Molecular studies on bone with focus on fracture healing in experimental  osteoporosis by Melhus, Gunhild
INSTITUTE OF PATHOLOGY,  
OSLO UNIVERSITY HOSPITAL RIKSHOSPITALET 
Molecular studies on 
bone with focus on 
fracture healing in 
experimental  
osteoporosis 
PhD thesis 
 
Gunhild Melhus 
cand. med. 
2/1/2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Gunhild Melhus, 2010 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 941 
 
ISBN 978-82-8072-509-7 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AiT e-dit AS.  
 
Produced in co-operation with Unipub.  
The thesis is produced by Unipub merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 

TABLE OF CONTENTS 
 2
TABLE OF CONTENTS 
TABLE OF CONTENTS.............................................................................................2 
ACKNOWLEDGEMENTS .........................................................................................4 
ABBREVIATIONS ....................................................................................................6 
PUBLICATIONS INCLUDED .....................................................................................8 
I. Experimentally osteoporosis induced by ovariectomy and vitamin D 
deficient diet does not markedly affect fracture healing in rats. .....................8 
II. Heat-induced retrieval of immunogold labeling for nucleobindin and 
osteoadherin from Lowicryl sections of bone.................................................8 
III. Key bone remodelling markers in the callus of vitamin D depleted 
ovariectomized rats .........................................................................................8 
IV. Chondroadherin deficient mice display a distinct bone phenotype ..........8 
1 INTRODUCTION ...................................................................................................9 
1.1 Bone..............................................................................................................9 
1.1.1 Bone cells .............................................................................................10 
1.1.2 Bone and cartilage extracellular matrix ...............................................13 
Table 1B. Noncollagenous proteins in bone and cartilage1 ..........................16 
1) Proteoglycans............................................................................................16 
3) Glycosylated proteins with cell attachment activities ..............................17 
4) Gla-containing proteins ............................................................................18 
1.1.3 Bone mineralization .............................................................................18 
1.2 Bone growth and remodelling..................................................................20 
Table 1C. Effects of cytokines and hormones on bone remodelling through 
RANKL and OPG secretion..........................................................................25 
1.4 Pathologic bone remodelling – osteoporosis...........................................29 
2 AIMS OF THE STUDY..........................................................................................32 
Specific objectives and hypotheses ................................................................32 
3 METHODOLOGY................................................................................................33 
3.1 Animal models...........................................................................................33 
3.1.1 Animal model of fracture healing in osteoporosis ...............................33 
3.1.2 Chondroadherin null mice....................................................................34 
3.2 Radiographic and biomechanical analyses.............................................35 
3.2.1 Dual X-ray absorptiometry (DXA) ......................................................35 
3.2.2 Micro computer tomography ...............................................................35 
3.2.3 Three-point cantilever bending test......................................................35 
3.3 Bone histomorphometry...........................................................................35 
3.4 Gene expression analyses .........................................................................36 
3.4.1 In situ hybridization .............................................................................36 
TABLE OF CONTENTS 
 3
3.4.2 DNA microarrays .................................................................................36 
3.5  Protein analyses -  immunohistochemistry............................................37 
3.5.1 Qualitative protein analysis..................................................................37 
3.5.2 Quantitative protein analysis................................................................37 
3.6 Statistical methods ....................................................................................39 
4 SUMMARY OF RESULTS.....................................................................................40 
4. 1 Paper I.......................................................................................................40 
Experimental osteoporosis induced by ovariectomy and vitamin D 
deficiency does not markedly affect fracture healing in rats ........................40 
4.2 Paper II ......................................................................................................40 
4.3 Paper III ....................................................................................................41 
Gene expression and distribution of key bone remodelling markers in the 
callus of estrogen-deficient vitamin D depleted rats.....................................41 
4.4 Paper IV.....................................................................................................41 
Chondroadherin-deficient mice present a distinct bone phenotype ..............42 
5 GENERAL DISCUSSION ......................................................................................43 
5.1 Methods .....................................................................................................43 
5.2 Results ........................................................................................................47 
6 CONCLUSIONS ...................................................................................................55 
7 FUTURE PERSPECTIVES ....................................................................................56 
8 REFERENCES .....................................................................................................58 
 
 
ACKNOWLEDGEMENTS 
 4
ACKNOWLEDGEMENTS 
 
The present study has been carried out at the Laboratory for Electron Microscopy 
and Laboratory for Immunohistochemistry and Immunopathology (LIPAT), 
Institute of Pathology, Oslo University Hospital Rikshospitalet. I started this 
work by participating in The Medical Student Research Program (MSR) in 
August 2003 to June 2006, which was jointly financed by the University of Oslo 
and The Research Council of Norway. I am grateful for the support and 
enthusiasm the head of the program Professor Jarle Breivik and the administrator 
and senior executive officer Maje Siebke have shown throughout these 3 years. 
After graduating from Faculty of Medicine at University of Oslo in June 2007, I 
was granted a PhD scholarship by the Norwegian South-Eastern Regional Health 
Authority extending to December 2009. I would like to express my gratitude 
toward both institutions. 
 
The insights and comments of a great number of people have proved invaluable 
to the different aspects of this work. The thesis has benefited greatly from your 
generous support, criticism, and technical assistance. The following people, 
however, deserve special recognition.  
 
Professor Finn P. Reinholt, my eminent and inspiring tutor, has been hands-on 
throughout the entire project. His enthusiasm and genuine interest proved durable 
and lasting; his office door was never shut and his cell phone was never off. He 
has generously shared his insight and knowledge, which extend far beyond the 
field of pathology, and asked all the right questions that helped move this project 
forward. I thank Finn for his medical and scientific competence, his perspective 
on life, and not least, his unforgettable one-liners. 
 
Lars Nordsletten, Jan Erik Madsen, Sigbjørn Dimmen, Lene Solberg, Göran 
Andersson, Dick Heinegård, Lovisa Hessle, Christiane Petzold, Rune Jemtland, 
Christina Wenglen, Mikael Wendel, Espen S Bækkevold and Sverre-Henning 
Brorson, my co-authors, have all greatly contributed to the work. By sharing 
their extensive knowledge they have enriched and helped develop the project. I 
would like to give special thanks to Espen, who taught a much appreciated crash 
course on in situ hybridization and with great patience spent hours supervising 
the setting up of the protocol, and Sverre, my second tutor, who in virtue of his 
genuine interest for electron microscopy and infinite patience has been a solid 
source of help and inspiration at all times, and Lene, for sharing the ups and 
downs of the working days in the research program, and for making it cool to be 
a nerd.  
 
ACKNOWLEDGEMENTS 
 5
Furthermore, a big thank-you goes to Linda Dorg, whose wit and honest 
feedback turned the strenuous lab-work into, if not a walk in the park, at least a 
pleasant hike, and Aileen Murdoch-Larsen, for her great attitude and her never-
ending willingness to help with the electron microscope and preparation of the 
material, and Linda I. Solfjell, for answering mundane questions and helping a 
despaired physician through the jungle of molecular biology (and for teaching 
me all about the social importance of soccer…). 
Furthermore, statistician John Michael Gran suggested valuable solutions to 
statistical challenges and provided excellent advices.  
 
Lastly, my best friend and soon-to-be husband, Petter A. Stordalen, a closeted 
academic with a well-hidden desire for a doctoral title (at least in the family), has 
endured my hardship. He put up with me through tough times and supported this 
project in every way conceivable. He has spent days and nights stimulating his 
self-declared insatiable interest in metabolic bone diseases, thereby gaining an 
insight into the research questions and an appreciation of the challenges along the 
way. Not once has he expressed any negative feelings toward the project or any 
wish for me to become a stay-at-home wife. His disposition and outlook have 
helped me transform my frustrations into optimism and confidence. As my rock-
solid mentor and inexhaustible source of positivity and inspiration, Petter, who in 
keeping with his feminist mindset now has earned the right to call himself Herr 
Doktor Melhus, added the finishing touch by writing the concluding paragraph 
himself. 
 
ABBREVIATIONS 
 6
ABBREVIATIONS 
 
1,25(OH)2D3 1,25-dihydroxyvitamin D3 
25(OH)D 25-hydroxyvitamin D 
ALP Alkaline phosphatase 
ANOVA Analysis of variance 
BMD Bone mineral density 
BMPs Bone morphogenic proteins  
BMUs Basic multicellular units  
BSP Bone sialoprotein 
BSA Bovine serum albumin 
BV1 Low-density bone 
BV/TV Normalized volume of high-density bone  
Cbfa1/Runx2 Runt-related transcription factor 2  
cDNA Complimentary DNA 
CHAD Chondroadherin 
COMP Cartilage oligomeric matrix protein 
COX-2 Cyclooxygenase 2 
cRNA Complementary RNA  
CS Chondroitin sulphate 
CTK Cathepsin K 
DAB+ Diaminobenzidine 
DIG Digoxigenin 
DMP1 Dentin matrix protein 1 
DXA Dual X-ray absorptiometry 
ECM Extracellular matrix 
FC Fold changes 
FDA U.S. Food and Drug Administration 
FGFR Fibroblast growth factor receptor 
FGF Fibroblast growth factor  
FS Freeze-substitution 
GAG Glycosaminoglycan 
HAP Hydroxyapatite 
HPF High-pressure freezing 
HPF-FS High-pressure freezing with freeze-substitution 
HPR Horseradish peroxidise 
IGF Insulin-like growth factor 
IHC Immunohistochemistry 
Ihh Indian hedgehog  
IL Interleukin 
ABBREVIATIONS 
 7
ISH In situ hybridization 
KO Knockout mice 
LM Light microscopy 
LRR Leucine-rich repeat 
MANOVA Multivariate analysis of variance 
M-CSF Macrophage-colony stimulating factor 
MEPE Matrix extracellular phosphoglycoprotein 
Micro-CT Micro-computer tomography 
MMPs Metalloproteinases 
MSC Mesenchymal stem cell 
NCPs Non-collagenous proteins 
NPP1/PC-1 Nucleotide pyrophosphatase phosphodiesterase 
NSAIDs Non-steroid anti-inflammatory drugs 
NUC Nucleobindin 
OPG Osteoprotegerin 
OPN Osteopontin 
OSAD Osteoadherin 
OVX Ovariectomy/ovariectomized 
PCR Polymerase chain reaction 
PDGF Platelet derived growth factor 
PF Paraformaldehyde 
PGs Proteoglycans 
Pi Inorganic phosphate 
PPi Pyrophosphate  
pQCT Peripheral quantitative computed tomography  
PS Phosphatidyl serine 
PTH Parathyroid hormone 
PTHrP PTH related peptide  
RANK Receptor activator of nuclear factor κβ  
RANKL Receptor activator of nuclear factor κβ ligand 
ROI Region of interest 
SD Standard deviation 
SIBLING Small integrin-binding ligand, N-glycosylated protein 
SLRP Small leucine-rich proteoglycan 
TEM Transmission electron microscopy 
TGF-β Transforming growth factor β 
TNAP Tissue non-specific alkaline phosphatase 
TNFα Tumor necrosis factor α  
TRAP Tartrate-resistant acid phosphatase 
VEGF Vascular endothelial growth factor 
VvTB Volume density of trabecular bone  
WT Wild type mice 
PUBLICATIONS INCLUDED 
 8
PUBLICATIONS INCLUDED 
I. Experimental osteoporosis induced by ovariectomy and vitamin D 
deficient diet does not markedly affect fracture healing in rats. 
Melhus G*, Solberg LB*, Dimmen S, Madsen JE, Nordsletten L, Reinholt FP.  
* The authors contributed equally to the manuscript 
 
Acta Orthop. 2007 Jun;78(3):393-403.  
 
 
II. Heat-induced retrieval of immunogold labelling for nucleobindin and 
osteoadherin from Lowicryl sections of bone 
Solberg LB*, Melhus G*, Brorson SH, Wendel M, Reinholt FP. 
* The authors contributed equally to the manuscript 
 
Micron. 2006;37(4):347-54. Epub 2005 Dec 9. 
 
 
III. Key bone remodelling markers in the callus of vitamin D depleted 
ovariectomized rats  
Melhus G, Brorson SH, Baekkevold ES, Jemtland R, Andersson G, Reinholt FP 
 
Calcif Tissue Int. (submitted) 
 
IV. Chondroadherin-deficient mice display a distinct skeletal phenotype 
Melhus G*, Hessle L*, Wenglen C, Petzold C, Brorson SH, Baekkevold ES, 
Reinholt FP, Heinegard D 
* The authors contributed equally to the manuscript 
 
 
Manuscript, 2010 
 
 
1 INTRODUCTION 
 9
1 INTRODUCTION 
1.1 BONE  
Bone is a dynamic mineralized connective tissue that together with cartilage 
forms the skeletal system which provides both structural and metabolic functions. 
Anatomically, bones can be classified as either long (humerus, tibia, femur) or 
flat (skull bones and mandible, scapula, rib cage, pelvis and sacrum). At the 
morphological level, bone can be divided into woven and lamellar. Woven bone 
is formed during embryonic growth and during fracture healing, and is made up 
of irregularly deposited collagen fibers. Woven bone is replaced with mature 
lamellar bone with orderly deposition of the collagen fibers in a highly organized 
parallel or concentric layered structure. Lamellar bone exists as either cortical 
(compact) or trabecular (spongy or cancellous) bone. Cortical bone makes up the 
hard outer shell of flat bones and the diaphyses of long bones, accounting for 
approximately 80% of the total bone mass in the adult. It is characterized by a 
slow turnover rate and high resistance to bending and torsion. The remaining  
20 % is trabecular bone, with low density but high surface area, is found in the 
interior of flat bones and in the metaphyses of long bones. Rod- and plate-like 
bone elements compose a spongy network housing the red bone marrow, which 
plays an important role in haematopoiesis. Trabecular bone is less dense, more 
elastic and has a higher turnover rate than cortical bone, providing the initial 
supplies of mineral to the systemic circulation in states of acute deficiency.  
 
A long bone consists of two epiphyses, connected by the diaphysis (shaft) via the 
metaphyses (fig 1.1). During bone growth, a cartilaginous growth plate is present 
at the epiphysis/metaphysis interface. After onset of puberty, the growth plate 
closes, leaving a thin residual growth line in the adult. The diaphysis is a cortical 
cylinder containing bone marrow. The epiphyses consist of trabecular bone 
covered with a thin cortical layer. The periosteum lines the outer bone surface, 
except at articular surfaces and insertion sites for ligaments and tendons. 
Endosteum lines the marrow cavity. 
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Fig. 1.1 (from http://www.bbc.co.uk/schools/gcsebitesize/pe/images/bone_anatomy.gif) 
1.1.1 Bone cells 
Bone cells originate from two different sources; mesenchymal progenitor cells 
which give rise to the osteoblastic lineage (osteoblasts, osteocytes and lining 
cells), and precursor cells related to the monocyte-macrophage cell line from the 
bone marrow differentiating into osteoclasts.   
 
The osteoblast is a cuboidal mononuclear cell, responsible for bone formation by 
synthesizing the main components of the extracellular matrix (ECM), i.e. 
collagen and non-collagenous proteins. Osteoblasts are found in clusters along 
the bone surfaces, lining the layer of bone matrix they are synthesizing. Runt-
related transcription factor 2 (Cbfa1/Runx2) and a downstream factor, osterix, are 
essential to osteoblast differentiation. In the process of bone formation, some 
osteoblasts become embedded in their own synthesized osteoid, and subsequently 
differentiate into the terminal stage of the osteoblastic cell lineage, becoming an 
osteocyte. Simultaneously, other cells undergo apoptosis or remain on the bone 
surface, becoming flattened lining cells. Morphologically, osteoblasts are 
characterized by a rounded nucleus, abundant rough endoplasmatic reticulum, an 
extensive Golgi apparatus as well as lysosomes. The expression of alkaline 
phosphatase (ALP) in the mature osteoblast disappears if the cell differentiates 
into an osteocyte.  
 
The osteocyte is the most abundant cell type in bone. Osteocytes are contained in 
separate lacunae throughout the bone, but create a functional communicative 
network enabling cross-talk between the various types of bone cells by sending 
out thin cytoplasmatic extensions traversing mineralized bone via thin canals, so-
called canaliculi. Osteocytes are involved in the biomechanical regulation of 
bone mass and structure, probably by sensing bone deformation, pressure, fluid 
flows and streaming potentials. Osteocytes typically express molecules such as 
1 INTRODUCTION 
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dentin matrix protein 1 (DMP1) (4) and matrix extracellular phosphoglycoprotein 
(MEPE) (5). MEPE is an inhibitor of mineralization (6), whereas DMP1 is 
produced by the osteocyte in a mechanically sensitive manner (7), and influences 
phosphate homeostasis through control of fibroblast growth factor 23 (FGF23).   
 
The bone lining cells are flat elongated cells covering quiescent bone surfaces. 
Their function is not fully understood, but they may 1) participate in the 
regulation of substrate exchange between the bone fluid compartment and the 
extracellular fluid of bone marrow,  2) respond to mechanical signals and 
mediate communication between the osteocyte network and the pool of 
osteoclasts and thereby initiating bone resorption or 3) serve catabolic functions 
(8). 
 
Osteoclasts are giant multinucleated cells responsible for bone resorption, 
formed by fusion of mononuclear progenitors of the monocyte-macrophage 
lineage. Two hematopoietic cytokines, macrophage-colony stimulating factor 
(M-CSF) and receptor activator of nuclear factor κβ ligand (RANKL) are 
necessary and sufficient for differentiation of macrophage precursors into mature 
osteoclasts. Osteoclasts contain abundant Golgi complexes, mitochondria and 
transport vesicles loaded with lysosomal enzymes. Non-resorbing osteoclasts are 
motile and show no distinct membrane domains. Prior to bone resorption, the 
osteoclast polarizes due to changes in the cytoskeleton and forms three distinct 
plasma membrane domains, i.e. the clear (sealing) zone on the apical side where 
the cell membrane pastes tightly to the bone surface, sealing off a compartment 
underneath the cell. In the cell membrane overlying this isolated compartment, 
numerous thin finger-like extensions form and make up the ruffled border, where 
the actual bone resorption occurs. Simultaneously, a functional secretory domain 
forms on the basolateral side of the cell. The initial attachment of osteoclasts to 
bone surfaces involves binding of integrins to specific amino acid sequences 
(RGD) within proteins such as osteopontin (OPN) at the matrix surface (9). 
Carbonic anhydrase II generates protons (H+) in the osteoclast cytoplasm, and 
these protons are transported into acidic vesicles through the action of a vacuolar-
type ATPase proton pump (V-ATPase) localized in the membrane of the vesicles 
(10). The migration and subsequent fusion of these acid-containing vesicles with 
the cell membrane form the ruffled border, and the contents of the vesicles are 
released into the resorption (Howship’s) lacuna. The active secretion of protons 
acidifies the environment and solubilises the mineral crystals, exposing the 
organic matrix for degrading proteases, and providing the pH optimum for the 
action of these proteases. of the organic matrix is cathepsin K (CTK) (11). The 
degradation products are endocytosed from the ruffled border, transported 
through the cell, and finally secreted into the extracellular space through the 
functional secretory domain (12-13). Osteoclasts also contain large amounts of 
tartrate-resistant acid phosphatase (TRAP), a metallophosphatase secreted into 
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the resorption lacunae. When activated by proteolytic processing, TRAP exhibits 
protein phosphatase activity towards matrix proteins such as OPN (14), and 
TRAP has recently been suggested to regulate osteoclast motility by 
dephosphorylation of OPN in the matrix (15).  
 
Figure 1.2: Osteoclastic bone resorption 
The osteoclast adheres to bone via binding of RGD-containing proteins (green 
triangle) to the integrin αvß3, initiating signals that lead to insertion into the 
plasma membrane of lysosomal vesicles that contain cathepsin K (Ctsk). 
Consequently, the cells generate a ruffled border above the resorption lacuna, 
into which is secreted hydrochloric acid and acidic proteases such as cathepsin 
K. The acid is generated by the combined actions of a vacuolar H+ ATPase 
(red arrow), its coupled Cl– channel (pink box), and a basolateral 
chloride/bicarbonate exchanger. Carbonic anhydrase converts CO2 and H2O 
into H+ and HCO3–. 
(From http://www.biology-online.org/articles/skin_bone/figures.html) 
1 INTRODUCTION 
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1.1.2 Bone and cartilage extracellular matrix  
Bone cells are surrounded by an organic ECM, strengthened by mineral deposits, 
mainly present in the form of hydroxyapatite (HAP) crystals [Ca10(PO4)6(OH)2]. 
Bone mineral comprises approximately 70% of the dry weight of bone. The 
organic phase contains mainly type I collagen fibers (which comprises 90% of 
the organic bone matrix), various noncollagenous proteins (NCPs), serum 
proteins and proteoglycans (PGs). In addition, small amounts of water and lipids 
are present. In a similar manner, cartilage cells are embedded in an abundant 
ECM, where collagen type II is the dominating collagen (for references, see 
(16)).  
 
Collagens (table 1A) 
Collagen is a triple helical molecule containing three identical or two or three 
different α chains depending on the collagen type. Collagen α chains is 
characterized by a Gly-X-Y repeating triplet where Y is often proline. Each of 
the different collagen chains has its own unique structure of this repeating triplet. 
After synthesis, the chains are extensively modified inside the cell by enzymes 
that add a variety of additional molecules (i.e. post-translational modifications). 
After assembly into fibrils, collagen chains exit the cell, and globular regions at 
both ends of the triple helix are cleaved by specific proteases leaving a shortened 
triple helical chain. Extracellularly, the triplex undergoes further modification 
with intra- and intermolecular crosslinks. The fibrils are then further arranged in 
collagen fibers forming a highly ordered network providing elasticity and 
flexibility. In addition, different types of collagen often interact at fibril surfaces 
also exposing domains for interaction with other extracellular matrix 
components. A variety of the NCPs influence the fibril formation 
 
Table 1A. Collagens in bone and cartilage 
 
Protein  Gene Distribution and suggested 
function 
Type I COL1A1, COL1A2 Most abundant protein in bone, 
serves as scaffold, binds and orients 
other proteins regulating central 
processes like mineralization 
Type II COL2A1 The key component of hyaline 
cartilage; contributes to the 
regulation of chondrocyte function, 
including differentiation, 
proliferation, and survival through 
cell-surface signalling mechanisms. 
Predominates in interterritorial 
matrix (composed of fibrillar 
collagen network providing tensile 
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strength) with type XI and type IX 
(17)  
Type III COL3A1 Present in bone in trace amounts, 
may regulate collagen fibril 
diameter, paucity in bone may 
explain the large diameter size of 
bone collagen fibrils 
Type V COL5A1, COL5A2, 
COL5A3 
Found in tissues containing type I, 
and tends to regulate the assembly 
of heterotypic fibers composed of 
both type I and type V 
Type VI  Predominates in the territorial 
matrix (close to the cell, consists of 
little or no fibrillar collagen) as 
microfibrils  
Type IX COL9A1 
COL9A2 
COL9A3 
Major component of hyaline 
cartilage 
Type X COL10A1 Present in hypertrophic and 
mineralizing cartilage, expressed 
by hypertrophic chondrocytes 
during endochondral bone 
formation and in the growth plate  
Type XI COL11A1 Produced by chondrocytes in the 
upper growth plate zones 
Type XXVII COL27A1 A novel member of the fibrillar 
collagen family, contributes to a 
stable cartilage matrix (18). 
 
Noncollagenous proteins in bone and cartilage 
Various NCPs account for the remaining 10% of the organic matrix, and are a 
heterogeneous group of proteins varying from entrapped serum protein to 
glycoproteins, which are unique to bone and/or cartilage. The NCPs are 
embedded in the matrix during bone and cartilage formation (some of them bind 
to collagen) and are released during resorption, participating in the remodelling 
process. Approximately 25% of the total NCP content is exogenously derived 
(table 1B,6). The remaining NCPs are locally produced by the cells, which 
synthesize collagen and NCP molecules in a 1:1 ratio. These NCPs can be 
divided into 5 groups: 1) PGs, 2) glycosylated proteins, 3) glycosylated proteins 
with cell attachment activities, and 4) γ-carboxylated (gla) proteins (19). In 
addition, the matrilins are regarded as a separate group of NCPs (table 1B,1-5). 
In cartilage, the collagen fibers are embedded in a hydrated gel of PGs and other 
glycoproteins. The PGs are essential for protecting the collagen network. The 
predominant glycosaminoglycan (GAG) of PGs in articular cartilage is 
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chondroitinsulfate (CS), along with aggrecan being the most abundant CS 
proteoglycan in the matrix of articular cartilage. Aggrecan forms complexes with 
hyaluronic acid, providing compressive resistance to the tissue. A large number 
of NCPs present in bone are also expressed in cartilage. However, some 
cartilage-NCPs are not expressed in bone, e.g. cartilage oligomeric matrix protein 
(COMP) and perlecan. The NCPs are regulated by several other molecules such 
as matrix metalloproteinases (MMPs), growth factors, transforming growth 
factor β (TGF-β), and bone morphogenic proteins (BMPs).  
 
1) Proteoglycans 
The PGs are macromolecules with acidic sugar side chains attached to a central 
core protein, which modulate cellular behaviour either through the attached GAG 
chains or by direct protein-protein interactions via the core protein sequences. In 
this group, we find among others, versican, decorin, biglycan, hyaluronan (a 
GAG, i.e. not attached to a protein core) and perlecan. In addition, there are other 
small leucine-rich proteoglycans (SLRPs) in bone, such as osteoglycin, 
osteoadherin, lumican, asporin and fibromodulin. The distinguishing feature of 
SLRPs is the presence of a central domain containing leucine-rich repeats 
(LRRs) in the protein core. The SLRPs play roles in biological processes, such as 
skeletal growth, craniofacial structure, and collagen fibrillogenesis (20).  
 
2) Glycosylated proteins 
ALP is a glycoprotein-enzyme highly expressed in bone, and believed to play a 
role in mineral deposition. Osteonectin, the most abundant protein in bone, is 
also a phosphorylated glycoprotein.  
 
3) Glycosylated proteins with cell attachment activities 
Bone cells synthesize at least 12 proteins that may mediate cell attachment: the 5 
members of the small Integrin-binding ligand, N-glycosylated protein 
(SIBLING) family, type I collagen, fibronectin, thrombospondin(s), vitronectin, 
fibrillin, BAG-75 and osteoadherin (which is also a PG). Common for most of 
these proteins is that they contain RGD (arginine–glycine–aspartate), the cell 
attachment sequence that binds to integrins in cell membranes. The SIBLING 
family includes OPN, bone sialoprotein (BSP), DMP1, dentin 
sialophosphoprotein and MEPE. Except from MEPE, these proteins are acidic, 
phosphorylated and secreted proteins. SIBLINGs bind strongly to bone mineral, 
and contain the RGD motif (21). The SIBLINGs are believed to play key 
biological roles in the development, turnover and mineralization of bone and 
dentin.  
 
4) Gla-containing proteins 
Matrix Gla-protein, osteocalcin and protein S (primarily synthesized by the liver, 
but also by bone cells) are post-translationally modified by the action of vitamin 
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K-dependent γ-carboxylases. The di-carboxylic glutamyl (gla) residues enhance 
calcium binding.  
 
Table 1B. Noncollagenous proteins in bone and cartilage1 
1) Proteoglycans  
 
Protein  
(gene symbol) 
Tissue distribution  Suggested function(s) in bone 
and/or cartilage 
Decorin (Dcn) Widely distributed Role in ECM assembly  
Biglycan (Bgn) Bone and connective 
tissues 
Modulation of matrix 
mineralization by modulating 
collagen assembly (22) 
Versican (Vcan) Secreted by many cell 
types 
Important in chondrogenesis (23) 
Perlecan 
(Hspg2) 
Cartilaginous tissues Interaction with matrix 
components to regulate cell 
signalling (24) 
Fibromodulin 
(Fmod) 
Widely distributed in 
connective tissues 
Binding to collagen type I, 
regulation of collagen fibril 
formation 
Asporin (Aspn) Periosteum and dental 
follicles during 
development 
Regulation of the initial deposition 
of hydroxyapatite in the collagen 
gap regions in vitro (25)  
Lumican (Lum) Widely distributed in 
connective tissues 
Collagen binding, regulate 
collagen organization (26) 
Chondroadherin 
(Chad) 
Mainly in cartilage 
matrix, but also in 
bone and other tissues  
Role in regulation of chondrocyte 
growth and proliferation  
Aggrecan 
(Acan) 
Cartilage-specific  Mediation of cell – cell and cell – 
matrix interactions, inhibitor of 
mineralization 
 
 
2) Glycosylated proteins 
 
Protein  
(gene symbol) 
Tissue distribution  Suggested function(s) in bone 
and/or cartilage 
Osteonectin 
(Sparc) 
Widely distributed,  
particularly at sites of 
remodelling and 
matrix assembly 
Regulation of collagen 
organization, regulation of bone 
formation and remodelling (27)   
Alkaline Bone, liver, kidney Potential calcium ion carrier, 
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phosphatase 
(Alpl) 
hydrolyzes inhibitors of mineral 
deposition 
 
3) Glycosylated proteins with cell attachment activities 
 
Protein  
(gene symbol) 
Tissue distribution  Suggested function(s) in bone 
and/or cartilage 
Osteopontin 
(Spp1) 
Widely distributed Cell (osteoclast) binding, regulator 
of mineralization   
Bone 
sialoprotein 
(Ibsp) 
Mineralized tissues Cell binding, initiation of 
mineralization  
Dentin matrix 
protein-1 
(Dmp1) 
Bone, dentin and non-
mineralized tissues  
Regulatory role in dentin 
mineralization and Pi homeostasis 
(28), no known function in bone  
Dentin 
sialophospho-
protein (Dspp) 
Tooth, bone, kidney 
and salivary glands 
 
Role in initial mineralization and 
remodelling of bone (29).  
Matrix 
extracellular 
phosphoglyco-
protein (Mepe) 
Bone and teeth  Role in bone homeostasis  
Fibronectin (Fn) Expressed in a variety 
of tissues 
Cell adhesion, growth, migration 
and differentiation 
Thrombo-
spondin-2 
(Thbs2) 
Expressed in a variety 
of tissues 
Promotion of mineralization (30) 
Vitronectin 
(Vtn) 
Mineralized bone, and 
several other tissues 
Regulation of bone metabolism 
(31) 
Fibrillins 
 
Expressed in a variety 
of tissues 
Role in cartilage development (32) 
Bone acidic 
glycoprotein-75 
 
Restricted to actively 
forming primary or 
woven bone and dentin  
Delineation of future extracellular 
sites of mineralization together 
with BSP (33) 
Osteoadherin/ 
Osteomodulin 
(Omd) 
Specific to mineralized 
tissues 
Cell binding, role in 
mineralization 
(is also a PG)  
Cartilage 
oligomeric 
matrix protein 
(Comp) 
Expressed in cartilage, 
ligament, and tendon 
Interaction with fibronectin, a role 
in ECM assembly by molecular 
interactions  
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4) Gla-containing proteins 
 
Protein  
(gene symbol) 
Tissue distribution  Suggested function(s) in bone 
and/or cartilage 
Matrix Gla 
protein (Mgp) 
Bone and cartilage, but 
expressed in many 
connective tissues 
Inhibitor of extracellular matrix 
calcification (34)  
Osteocalcin 
(Bglap) 
Most abundant NCP in 
bone, secreted by 
mineralized tissues 
Participation in mineralization and 
cell signalling, recruiting 
osteoblasts and osteoclasts (35)  
 
5) Matrilins  
 
Protein  
(gene symbol) 
Tissue distribution  Suggested function(s) in bone 
and/or cartilage 
Matrilins 
(Matn) 
Matrilin-1 and -3 
specific to cartilage 
Role as adaptor proteins mediating 
interactions between collagens and 
proteoglycans (36-37) 
 
6) Exogenously derived serum proteins 
 
Protein  
(gene symbol) 
Tissue distribution  Suggested function(s) in bone 
and/or cartilage 
α2HS-
glycoprotein 
(Ahsg) 
Widely distributed 
protein from liver 
Regulation of bone mineralization  
 
Albumin Widely distributed 
protein from liver  
Inhibition of growth of bone 
mineral crystals 
1 The exact role of most proteins is not known, and the official gene symbols (for 
Rattus norvegicus) and suggested functions are referred from 
www.ncbi.nlm.nih.gov/gene if no other reference is given.  
 
1.1.3 Bone mineralization 
Mineralization occurs by the orderly deposition of HAP at discrete sites in the 
collagenous network, where mineralization nodular complexes form within 48 – 
72 h (38). Crystals are always deposited so that their longest dimension lies 
parallel to the axis of the collagen fibrils. Formation of the initial HAP crystal, 
i.e. the “critical nucleus”, is the most energy demanding step in the process, 
requiring the ions of the future crystal to fuse with proper direction and sufficient 
energy, and is believed to occur at the gap (“hole”) zones between collagen 
fibrils.   
Because body fluids are undersaturated with respect to HAP, crystals will not 
precipitate spontaneously. Thus, promoters and/or local factors in the ECM are 
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required to facilitate initiate crystal formation. Two current hypotheses of critical 
nucleus formation exist; 1) Passive de novo formation, where local 
mineralization inhibitors are overwhelmed (39), and 2) heterogeneous nucleation, 
i.e. active contribution to crystal formation by local extracellular nucleation 
complexes such as mineralization foci (40), crystal ghosts (41), matrix vesicles 
(41-42), or ECM phosphoproteins (42-43). 
 
Matrix vesicles 
Matrix vesicles are generally accepted to play a role during mineralization of 
vertebral hard tissues, although to a lesser extent in bone compared to cartilage 
and tendon (44). They are small (20 – 200 nm) spherical bodies observed in the 
pre-mineralized matrix of dentin, cartilage and bone, derived from the plasma 
membrane of chondrocytes, osteoblasts and odontoblasts. They contain a 
nucleation core consisting of acidic phospholipids, calcium, inorganic phosphate 
(Pi), annexins (Ca-transport proteins), and are also enriched in tissue non-specific 
alkaline phosphatase (TNAP), nucleotide pyrophosphatase phosphodiesterase 
and phosphatidyl serine in addition to several MMPs. The vesicles may provide 
protected areas to enhance the concentration of Pi and calcium, and/or remove 
the inhibitory effect of pyrophosphate (PPi) on HAP formation (45-47). On the 
outer membrane surface, TNAP hydrolyses PPi in the ECM, which inhibits HAP 
formation and yields free Pi which reacts with calcium to form HAP (42,48). 
Although regulation of extracellular PPi and Pi concentration is necessary for 
mineralization, TNAP is important but not sufficient , unless the enzyme is 
membrane-anchored (49).   
However, the mechanisms through which matrix vesicles initiate mineralization 
remain unclear, especially because they are not directly associated with the 
collagen fibrils where crystals are finally deposited.  
 
Role of matrix proteins  
It is now generally accepted that there are NCPs associated with collagen that can 
serve as nucleators and regulators of size and shape of HAP crystals. Members of 
the SIBLING family (in particular BSP and DMP1), osteonectin and BAG75 are 
all suggested to act as nucleators (44,50). Most of these molecules are acidic and 
capable of binding calcium ions. BAG75 delineates future sites of mineralization 
(33), and BSP, BAG75 (50) and TNAP form spherical structures in osteoblast 
cultures which represent mineralization foci. Other protein such as osteonectin, 
OPN and osteocalcin do not generally act as nucleators but bind to HAP with 
high affinity and act as effective inhibitors of crystal proliferation. However, 
even a highly phosphorylated form of OPN can act as a nucleator, while a small 
peptide of MEPE can act as an inhibitor of cell-mediated mineralization (51). It 
is thus likely that many of these proteins are modified locally to modulate the 
process of mineralization.  
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Once the critical nucleus is formed and large enough to persist in solution, ions 
or ion clusters are easily added in the process of crystal growth. In bone, there are 
obviously many such nucleation sites, as crystals form concurrently at numerous 
separate loci. Secondary nucleation occurs as new ions form on the initial 
nucleus in a manner analogous to that of glycogen branching. The new crystal 
branches separate and provide additional nuclei. When bone matures, the crystals 
increase in size and become more perfect (i.e. contain less impurities and thus are 
less soluble). While each of the major hypotheses of the initiation of 
mineralization is plausible and backed by a substantial body of evidence, the 
known features of cartilage and bone mineralization are still incompletely 
understood.  
 
1.2 BONE GROWTH AND REMODELLING  
 
1.2.1 Bone formation 
The future bony skeleton in the embryo is composed of either fibrous tissue or 
hyaline cartilage. Bone formation occurs by two distinct processes; 
intramembranous and endochondral pathways, which in general form flat and 
long bones, respectively (for references, see (52)).  
 
Intramembranous bone formation 
Mesenchymal cells migrate and condensate into clusters within the fibrous tissue, 
and differentiate directly into osteoblasts. Such a cluster is known as an 
ossification center, and the osteoblasts start to secrete matrix, which subsequently 
mineralize. Matrix synthesis continues until the osteoblasts are completely 
covered in immature, irregular matrix, forming a trabeculum. The woven bone is 
subsequently remodelled into mature lamellar bone. Mesenchymal cells continue 
to differentiate in the periphery. Other trabeculae form in nearby ossification 
centers and fuse into the open latticework characteristic of trabecular bone, and 
bone marrow develops in the intertrabecular areas by ingrowth of capillaries. The 
original connective tissue surrounding the growing bone mass, transforms into 
the periosteum, and eventually, the surface layers of trabecular bone are 
transformed into cortical bone. Much of this newly formed bone is subsequently 
modelled and remodelled until the bone reaches its final adult size and shape.   
 
Endochondral bone formation 
Endochondral bone formation occurs via an intermediate step of cartilage, and 
involves a coordinated set of interactions requiring the transient expression of 
specific genes and various cell – cell and cell – matrix interactions, which results 
in the eventual replacement of cartilage with bone. The process starts with 
proliferation and aggregation of mesenchymal cells at the site of the future bone, 
which in hypoxic areas differentiate into chondroblasts. The chondroblasts 
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secrete cartilaginous matrix that lead to development of a cartilage model of the 
future bone, lined with a membrane known as the perichondrium. Midway along 
the diaphysis, blood vessels start to penetrate the perichondrium, stimulating 
cells in the internal layer of the membrane to differentiate into osteoblasts. The 
osteoblasts deposit bone matrix making a bone collar around the diaphysis of the 
cartilage model. Thus, the perichondrium is transformed into the periosteum. 
Simultaneously, the primary ossification center develops centrally in the 
cartilaginous diaphysis where chondrocytes start to hypertrophy. Typical features 
of hypertrophic chondrocytes are the expression of type X collagen (53), 
increased synthesis of ALP (54), denaturation and removal of ECM, and a net 
increase in the production of MMPs over their tissue inhibitors. This is followed 
by blood vessel invasion and matrix calcification. The hypertrophic cells undergo 
apoptosis, matrix breaks down and an expanding marrow cavity ensues. 
Meanwhile, capillaries grow into the cavity and establish contact with bone 
marrow cells. The calcified matrix is partially resorbed and osteoblasts begin to 
deposit bone. Periosteal bone formation continues to increase the cortical 
thickness, while the cartilage model enlarges bilaterally at both ends. Ingrowth of 
blood vessels also occurs in the epiphyses and trabecular bone is formed, 
establishing the two secondary ossification centers within the epiphyses. After 
formation of the secondary ossification centers, the cartilage model is completely 
replaced by bone except at the articular surfaces, which are permanently covered 
with cartilage, and at the epiphysis/diaphysis interface, where cartilage persists as 
the epiphyseal growth plate. Bone elongation occurs by proliferation of cells at 
the epiphyseal side of the growth plate, where chondrocytes pass through various 
stages of differentiation, from a resting stage through proliferation, maturation, 
and finally hypertrophy, leading to replacement of cartilage with bone on the 
diaphyseal side. Thus, the thickness of the epiphyseal growth plate remains fairly 
constant but the diaphyseal bone continues to elongate. Increase in cortical 
diameter occurs by parallel periosteal appositional growth and endosteal 
resorption. Initially, diaphyseal and epiphyseal ossification form trabecular bone, 
but this is transformed into cortical bone. In humans, primary and secondary 
ossification centers fuse after puberty, whereas in adult rodents a narrow region 
of growth plate cartilage remains. 
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1.2.2 The epiphyseal growth plate 
The epiphyseal growth plate can be divided in 4 distinct zones. The resting (or 
reserve) zone is a source of mesenchymal stem cells, responsible for protein 
synthesis and maintenance of germinal structure. The proliferative zone is 
characterized by actively proliferating cells, arranged in regular vertical columns 
which synthesize matrix. The hypertrophic zone (divided in the upper and lower 
hypertrophic layers) contains chondrocytes that enlarge, separate and 
subsequently undergo apoptosis. In the calcifying zone, the remaining 
longitudinal septa of cartilage are subsequently mineralized by increased release 
of ALP, calcium and matrix vesicles by terminally differentiated chondrocytes. 
Metaphyseal vessels carrying osteoprogenitor cells grow in and the mineralized 
matrix is partially resorbed by chondroclasts. The osteoprogenitor cells 
differentiate and start to deposit woven bone on the cartilaginous septa, forming 
the primary spongiosa. The woven bone and cartilage are subsequently 
Figure 1.3: Endochondral bone growth 
Endochondral bone formation starts at discrete sites in the cartilage (i.e. the 
primary ossification centers) appearing during fetal development, although 
some short bones starts ossification post partum. The primary ossification 
center forms in the diaphyses of long bones, short bones and certain parts of 
irregular bones. Secondary ossification occurs post partum and forms the 
epiphyses of long bones and the extremities of irregular and flat bones. The 
diaphysis and both epiphyses are separated by a growing cartilaginous zone, 
i.e. the epiphyseal growth plate, which closes during puberty and cessation of 
longitudinal growth.  
http://www.mheresearchfoundation.org/sitebuilder/images/illu_bone_growth-740x379.jpg 
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remodelled and replaced by lamellar bone. This mature trabecular bone is called 
the secondary spongiosa. Estrogen secretion in both sexes at the onset of puberty 
is considered the main cause of cessation of growth by inactivating the growth 
plate, which is subsequently replaced by trabecular bone in most mammals. 
 
 
 
Regulation of the epiphyseal growth plate 
Molecular regulation of chondrocyte proliferation and hypertrophy include the 
“Indian hedgehog” (Ihh), parathyroid hormone (PTH) related peptide (PTHrP), 
Wnt, Fgf and Bmp signalling pathways (for references, see (52)).  
Sox9 and Runx2 are master transcription factors required for developing 
chondrocytes and osteoblasts from mesenchymal stem cells, respectively. 
Increased Wnt signalling takes place during intramembranous bone formation 
and promotes osteoblast differentiation, while decreased Wnt signalling favours 
chondrocyte differentiation. Ihh signalling is required for osteoblast 
differentiation. In contrast to Wnt and Ihh, BMP signalling stimulate both 
osteoblast and chondrocyte differentiation from mesenchymal progenitors. 
Fibroblast growth factors (FGFs) and FGF receptors (FGFRs) are also important 
mediators of bone formation although their exact roles are not fully elucidated. 
Ihh controls the pace of chondrocytes hypertrophy by activating PTHrP, which is 
synthesized in the perichondrium by terminally differentiated chondrocytes (52). 
Secondary to activation of PTH/PTHrP receptors, PTHrP stimulates cell 
proliferation by G protein activation and delays transformation into 
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prehypertrophic and hypertrophic chondrocytes. The feedback loop between Ihh 
and PTHrP regulates the balance between proliferating and hypertrophic 
chondrocytes, maintaining the growth plate at a constant width.  
 
 
1.2.3 Bone remodelling 
Bone remodelling is the process where the skeleton is continuously being 
renewed throughout its lifetime, allowing the maintenance of the shape, quality 
and size of the skeleton. Remodelling occurs asynchronously at multiple discrete 
sites throughout the skeleton, and is coordinated by multiple paracrine and 
autocrine factors (55). Remodelling occurs in order to 1) repair micro-fractures 
before they accumulate and lead to fatigue fractures under repeated cyclic 
loading (targeted remodelling), and 2) provide access to stores of calcium and 
phosphate, maintaining the mineral homeostasis (random remodelling) (56). 
Osteoclastic resorption is followed by osteoblastic formation in a tightly coupled 
process; these cell types work together in basic multicellular units (BMUs). The 
BMU undergo a stepwise remodelling cycle comprising activation, resorption, 
and formation, followed by a quiescent stage. In between resorption and 
formation, there is a reversal phase. Imbalance in the remodelling cycle is 
essential in the pathogenesis of several bone disorders, such as osteoporosis and 
Paget’s disease (57). The coupling of resorption and formation is based upon the 
RANK-RANKL-OPG axis. RANKL is a protein synthesized by cells in the 
osteoblastic lineage, and is present both in a membrane-bound and a soluble 
form. RANKL binds to its receptor, RANK (receptor activator of nuclear factor 
κβ), expressed by osteoclast precursors, thereby promoting osteoclast formation 
(58). A competitive soluble ligand for RANK, osteoprotegerin (OPG), also 
produced by osteoblastic cells, blocks activation of RANK and thus formation of 
active osteoclasts.  
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1.2.4 Local and systemic control of bone remodelling 
The calcium and phosphate ion storage role of the skeleton is helpful in 
understanding the complex regulation of bone remodelling.  
 
The main systemic factors influencing bone remodelling are PTH and vitamin D3 
(1,25(OH)2D3). Receptors for these hormones are expressed solely in osteoblasts, 
and these and other factors regulating bone resorption, signal to the 
osteoblast/stromal cells, which then translate these signals into different levels of 
RANKL and OPG expression (58-59). Thus, the “convergence hypothesis” refers 
to that OPG and RANKL can be the mediators for the stimulatory or inhibitory 
effects of a variety of systemic hormones, growth factors and cytokines on 
osteoclastogenesis. The activity of the resorptive and antiresorptive agents 
“converges” at the level of these two mediators, whose final ratio controls the 
degree of osteoclast differentiation, activation and apoptosis (60). A third 
hormone involved in mineral homeostasis, calcitonin, acts directly on osteoclasts, 
antagonizing the action of PTH and vitamin D3, thereby inhibiting bone 
resorption. 
Glucocorticoids exert both stimulatory and inhibitory effects on bone cells, being 
essential for osteoblast maturation by promoting differentiation from 
mesenchymal progenitors, but decrease osteoblast activity. Furthermore, 
glucocorticoids sensitize bone cells to regulators of bone remodelling and they 
augment osteoclast recruitment.  
Figure 1.5: Bone remodelling cycle 
The remodelling cycle consists of 3 consecutive phases: activation, resorption, 
during which osteoclasts digest old bone, followed by a reversal phase where 
mononuclear cells appear on the bone surface, and subsequently formation, 
when osteoblasts lay down new bone until the resorbed bone is completely 
replaced. 
(From www.umich.edu/news/Releases/2005/Feb05/bone.html) 
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Thyroid hormones stimulate both bone resorption and formation. Thus, 
hyperthyroidism may increase turnover which may result in bone loss. Estrogens 
protect the adult skeleton against bone loss by slowing the rate of bone 
remodelling (by attenuating the birth rate of osteoclast/osteoblast progenitors) 
and by maintaining a focal balance between bone resorption and formation (by 
exerting a proapoptotic effect on osteoclasts, and antiapoptotic effects on 
osteoblasts/osteocytes). Androgens are essential to skeletal growth and 
maintenance via receptors present in all types of bone cells (for references, see 
(61)).  
 
Mature osteoblasts express receptors for and are regulated in an autocrine and 
paracrine manner by a variety of growth factors such as insulin-like growth 
factors (IGFs), platelet-derived growth factor (PDGF), FGFs, TGF-β and the 
BMPs. A number of cytokines such as tumor necrosis factor α (TNF-α) and 
interleukin 10 (IL-10) modulate the RANK-RANKL-OPG system by stimulating 
macrophage colony-stimulating factor (M-CSF) production and by directly 
increasing RANKL expression (62). Furthermore, IL-6, a pleiotropic cytokine 
secreted by osteoblasts, osteoclasts and stromal cells, appears to be an important 
regulator of bone remodelling by stimulating osteoclastic bone resorption (63) 
but also by promoting osteoblast generation in conditions of high bone turnover 
(64). Furthermore, recent studies have suggested that osteoblast-derived PTHrP 
promotes the recruitment of osteogenic cells and prevents the apoptotic death of 
osteoblasts, thus being an important regulator of bone cell function (65).  
 
Table 1C. Effects of cytokines and hormones on bone remodelling through 
RANKL and OPG secretion  
 
Factor RANKL OPG 
TGF-β - ↑ 
PTH ↑ ↓ 
1,25(OH)2 vitamin D3 ↑ - 
Glucocorticoids ↑ ↓ 
Estrogen - ↑ 
FGFs ↑ ↓ 
Prostaglandin E ↓ ↑ 
 
 
1.3 BONE REPAIR – FRACTURE HEALING 
Fracture healing is a unique response to bone injury, which in contrast to repair 
of many other types of tissues, leads to the complete restoration of both anatomy 
and function without leaving a scar. In general, fracture healing is completed in  
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6 – 8 weeks after initial injury. Fracture healing may occur both through direct 
(intramembranous) or indirect (endochondral) bone formation.  
 
Fracture healing can be divided in four more or less overlapping stages. At the 
cellular level, inflammatory cells, vascular cells, osteochondral progenitors, and 
osteoclasts are key players in the repair process. At the molecular level, fracture 
repair is driven by the 3 main classes of factors: pro-inflammatory cytokines and 
growth factors, pro-osteogenic factors, and angiogenic factors (66), recruiting 
cells and stimulating growth and/or differentiation. Thereafter, the damaged soft 
tissues are repaired and the fracture is bridged by soft callus and later hard callus. 
The bridging hard callus is eventually remodelled to re-establish the original 
anatomy and function of the fractured bone.  
 
 
 
 
Figure 1.6. Stages of fracture healing 
(A) A representative series of images of the 4 stage-model of fracture healing. 
Between stage 2 and 3, the soft callus is systematically remodelled. (B) A 
detailed version of the anabolic/catabolic model of fracture repair that 
incorporates the concepts of non-specific anabolism (the early tissue repair 
process) and non-specific catabolism (soft callus remodelling). (C) A 
schematic illustration of the cellular contributors to the fracture repair process. 
The sources of mesenchymal progenitors that are able to differentiate into 
osteoblasts remain ambiguous (Figure from (3)). 
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Stage 1: Inflammation 
The acute bone injury is typically associated with damage also of soft tissue, 
interruption of blood vessels and distortion of the marrow cavity, leading to 
activation of non-specific tissue healing pathways. The first event is haematoma 
formation within the fracture site, with degranulating platelets, macrophages and 
inflammatory cells (granulocytes, lymphocytes and monocytes), which secrete 
cytokines/growth factors and advance  formation of  a stable fibrinous clot (67). 
Subsequently the clot is reorganized into granulation tissue with extensive 
ingrowth of capillaries, allowing macrophages and other phagocytic cells to clear 
degenerated cells and debris. Important regulators of this first stage include TGF-
β, PDGF, FGF-2, vascular endothelial growth factor (VEGF), M-CSF, IL1- and 
IL-6, BMPs and TNF-α (68). In addition, the expression of cyclooksygenase-2 
(COX-2) is critical to early stages of fracture healing (69-70). These factors 
contribute to further attraction of inflammatory cells, as well as multipotent 
mesenchymal stem cells (71). Periosteum (72), bone marrow (73), circulating 
blood (74) and surrounding soft tissue (75) have all been suggested as sources of  
stem cells.  
 
Stage 2: Soft callus (fibrocartilage) formation 
In completely stable fractures, healing can occur solely by intramembranous 
bone formation. However, at most fracture sites, there is some degree of 
instability between the fracture fragments, promoting endochondral bone healing 
(67). This stage is dominated on a cellular level by chondrocytes and fibroblasts, 
producing a semi-rigid soft callus providing mechanical support to the fracture 
and concurrently acting as a template for the subsequent bony callus. The 
cartilaginous callus is initially avascular, although replacement with woven bone 
involve vascular invasion. Mesenchyme-derived chondrocytes synthesize 
cartilaginous matrix, thereby replacing the granulation tissue with cartilage. In 
the absence of cartilage formation, fibroblasts replace the haematoma with 
fibrous tissue. The discrete cartilaginous areas expand to form a central 
fibrocartilaginous glue between the fracture fragments (66). Finally, the 
chondrocytes hypertrophy and mineralize the cartilaginous matrix before 
undergoing apoptosis. The proliferation and differentiation of fibroblasts and 
chondrocytes are stimulated by growth factors such as TGF-β2 and –β3, PDGF, 
FGF-1 and IGF. TGF-β1 is also critical, and decreased  serum levels are found in 
humans with delayed fracture healing (76). Additionally, various BMPs 
contribute to proliferation and chondrogenesis. In response to these factors, 
chondrocytes produce ECM components, particularly collagen II (and collagen X 
by hypertrophic chondrocytes) (77). Pro-angiogenic factors such as VEGF, 
BMPs, FGF-1 and TGF-β attract endothelial cells and stimulate angiogenesis 
(78). VEGF is important to fracture healing (79). The key bone and cartilage 
transcription factor Cbfa1/Runx2 is essential for VEGF expression by osteogenic 
cells (80) 
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Stage 3: Hard callus formation (primary bone formation) 
This stage represents the most active period of osteogenesis, with intense 
osteoblast activity and formation of mineralized bone matrix, which arises 
directly in the peripheral callus in areas of stability bridging the bone fragments. 
The soft callus is replaced with woven bone which becomes revascularized. 
Various BMPs are critical for the proliferation/ differentiation and ECM 
synthesis in osteoblasts, and are sufficient for de novo bone formation (81-82). 
Although other growth factors are expressed during this stage, their roles in 
promoting migration/proliferation and/or differentiation of osteoprogenitors 
remain unclear (67). Sufficient vascularization yielding increased local oxygen 
tension and thus promoting osteoblast differentiation is critical to formation of 
hard callus.   
 
Stage 4: Bone remodelling 
Remodelling of woven bone into its original lamellar cortical and/or trabecular 
configuration represents the last stage of fracture healing.  
 
Factors influencing fracture healing 
Fracture repair is affected by the degree of injury, the specific site, the fracture 
gap, and by type/stability of an eventual surgical fixation. Local biology, 
including the condition of the vasculature available at the site, and individual 
factors in the subject, such as age, gender, medication, and diseases, all affect 
fracture repair. Additional integral factors include viability of local tissue, 
vasculature, and access to stem cells. 
 
Factors that negatively affect fracture healing can be classified as injury- related, 
patient-related and surgery/surgeon-related factors (83). Injury- related factors 
include high energy trauma (84), soft tissue injury (85), complex fractures (86) 
and degree of obliquity (87). Patient-related factors include smoking (88), drug 
(e.g. NSAIDs (89)) and alcohol consumption (90), aging (70,91-92),  nutritional 
state (93) as well as underlying metabolic conditions e.g. diabetes mellitus (94) 
and hyperhomocysteinemia (95). Surgery-related factors include gap between 
fracture fragments (87), use of an open instead of a closed surgical technique, 
and persisting instability between fracture fragments.  
 
1.4 PATHOLOGIC BONE REMODELLING – OSTEOPOROSIS 
Osteoporosis is a multifactorial skeletal disease, characterized by reduction in 
bone mass and disruption of the microarchitectural structure of bone tissue, 
resulting in loss of mechanical strength and increased risk of fracture. The 
disorder can be localized or generalized, involving the entire skeleton. In the 
European Union, osteoporosis is a leading cause of mortality and morbidity in 
the elderly and a key factor in the high cost of medical care (96). Osteoporosis is 
defined by the World Health Organization in women as bone mineral density 
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(BMD) (g/cm2) 2.5 < standard deviations below young adult women (T-score < 
2.5), while a T-score between -2.5 and -1 is defined as osteopenia (97). T-score is 
defined as the measured BMD minus young adult mean BMD divided by the 
young adult standard deviation. Established osteoporosis includes T score < -2.5 
and the presence of one or more fragility fractures. Although BMD is strongly 
correlated to the risk of fracture (98-99), low BMD alone is not a sufficient 
predictor of fracture risk (100).   
 
Generalized osteoporosis can be classified as either primary or secondary. 
Primary osteoporosis is further divided into type I, which is postmenopausal in 
women and “idiopathic” in men, occurring in the 5th to 7th decade of life. Type I 
osteoporosis mainly affects trabecular areas and contributes in particular to 
vertebral and wrist fractures. It is associated with low trabecular bone mass and 
disturbed trabecular architecture. Also cortical bone mass is decreased and the 
diameter of the medullary cavity is expanded due to increased endocortical bone 
resorption overriding periosteal apposition. Type II, also known as senile 
osteoporosis, affects both trabecular and cortical bone in aged individuals 
(typically from the 7th decade), and predisposes to hip fractures. Secondary 
osteoporosis is related to other conditions such as hypogonadism, endocrine 
disorders, renal failure, rheumatic diseases, gastrointestinal disorders, 
osteomalacia, rickets and Paget’s disease (for references see (101-102)).  
 
After achieving peak bone mass in the late twenties, both sexes start to lose bone. 
Peak bone mass is mainly determined by genetic factors, but also influenced by 
environmental factors such as diet (vitamin D, calcium) and physical activity. 
Thus, individuals that do not achieve their genetically optimal bone mass have 
less bone to lose as a result of normal aging and suffer an increased risk of 
developing osteoporosis. In general, men have higher bone mass than women 
(thus more bone to lose), and are therefore prone to later onset of osteoporosis. 
Osteoporosis could be the consequence of a failure to reach peak bone mass in 
young adulthood, excessive resorption after peak bone mass is achieved, or 
impaired bone formation during remodelling (103). Postmenopausal osteoporosis 
is the consequence of withdrawal of the bone-sparing effect of estrogen, where 
resorption overrides bone formation.  
Age-related bone loss occur at most skeletal sites in both sexes, although pattern, 
magnitude and underlying cellular mechanisms differ markedly. In men, 
trabecular bone volume decreases with age and the individual trabeculae become 
thinner, but remains connected (104). This is associated with decreased rate of 
matrix deposition and increased duration of the bone formation phase during 
remodelling (105). The same trabecular thinning is observed in women until 
menopause, where the rate of bone loss accelerates due to cessation of estrogen 
production. Estrogen deficiency is associated with an increase in RANKL 
production by bone marrow osteoblastic, T and B cells (106), thereby enhancing 
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the bone turnover rate and the osteoclastic resorption. There is also an increase in 
the activation frequency of BMUs, and the enhanced osteoclast activity could 
also leads to deeper Howship’s lacunae. Thus, trabeculae are perforated and 
ultimately removed, resulting in reduced trabecular number and connectivity in 
women (107).  
Although an increase in bone diameter is seen with advancing age, the cortices 
attenuate because periosteal apposition is less than endocortical resorption (108).  
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2 AIMS OF THE STUDY  
The main aim of this thesis was to obtain a better understanding of some of the 
molecular mechanisms involved in bone remodelling/healing during 
physiological and a pathological state. 
 
SPECIFIC OBJECTIVES AND HYPOTHESES 
1. To examine whether experimental postmenopausal osteoporosis influences the 
healing of fractures as evaluated by histomorphometric, radiographic and 
mechanical parameters. Our hypothesis was that the combined withdrawal of 
estrogen and vitamin D will disturb and/or delay the healing process, resulting 
in impaired mechanical properties of callus.  
2. To enhance immunolabelling in electron microscopic studies of bone by 
retrieving epitopes by heating Lowicryl sections of paraformaldehyde (PF)-
fixed tissues prior to immunolabelling. Our hypothesis was that heating under 
controlled conditions will reveal more epitopes with retained tissue 
distribution. 
3. To examine whether experimental postmenopausal osteoporosis influences the 
molecular composition of the ECM in the fracture callus. Our hypothesis was 
that lack of estrogen and vitamin D deficiency influence global gene 
expression, as well as synthesis and ultrastructural distribution of ECM 
molecules in the callus, and consequently, the capacity of fracture repair.  
4. To learn more about the ECM protein chondroadherin (CHAD) using a gene 
knockout mouse model. Our hypothesis was that these knockout mice will 
show a distinct skeletal phenotype indicating specific roles for the protein in 
bone and cartilage metabolism.  
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3 METHODOLOGY 
Detailed descriptions of methods are provided in papers I-IV, respectively. 
General aspects of the main methods used for the work included in the thesis are 
presented in this section.   
 
Table 3.1 Overview over methods used in the thesis   
 
Paper Animals  Methods 
I OVX rats fed vitamin D 
deficient diet 
Tibial midshaft fracture, 
intramedullary nail 
In vivo DXA measurements 
Bone histomorphometry 
Three-point cantilever bending test 
 
II Normal rats 
 
Immunoelectron microscopy (NUC, 
OSAD) for retrieved and non-retrieved 
PF-fixed sections, and non-retrieved 
HPF-Fs sections 
III OVX rats fed vitamin D 
deficient diet 
Tibial midshaft fracture, 
intramedullary nail 
 
In situ hybridization (TRAP, CTK, OPN, 
BSP) 
Immunoelectron microscopy (TRAP, 
CTK, OPN, BSP) 
DNA microarrays 
IV CHAD null mice 
 
Histology 
Bone histomorphometry 
In situ hybridization (TRAP, CTK, OPN, 
BSP, COMP) 
Immunohistochemistry (COMP) 
Immunoelectron microscopy (OPN, BSP) 
Micro-CT 
 
3.1 ANIMAL MODELS  
All animal procedures were approved by the Norwegian or the Swedish Animal 
Research Authority.  
3.1.1 Animal model of fracture healing in osteoporosis 
In paper I and III, female rats, 10 weeks of age, were randomly assigned to 2 
groups; bilateral ovariectomy (OVX) and vitamin D3 deficient diet (OVX-D), or 
sham operation and normal diet (sham). After 12 weeks, a closed transverse tibial 
fracture was established in all animals during deep anaesthesia and stabilized 
with an intramedullary nail. OVX-D and sham animals were killed 3 and 6 weeks 
after fracture, and blood was collected for serum analyses of estradiol and 
25(OH)D.  
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3.1.2 Chondroadherin null mice (fig. 3.1) 
In paper IV, mice with the chondroadherin (CHAD) gene knocked out were 
examined. In brief, after isolating the CHAD gene from a mouse gene library, a 
similar but inoperable DNA gene and its neighbour sequence were engineered. 
Embryonic stem cells were combined with the new CHAD sequence and a 
targeting vector using electroporation. After growth in culture, positive clones 
were picked, expanded and purified, and DNA analyzed with Southern blot for 
confirmation of the correct targeting events. Targeted embryonic stem cells were 
injected to mouse blastocysts according to standard procedures. Chimeric males 
were matched with C57BL/6 and males with germ line transmission were further 
bred with 129/sv females to establish an inbred strand of CHAD null mice.   
 
 
 
 
 
Figure 3.1: Analyses of message and proteins in CHAD-/- and WT mice 
A: PCR and agarose electrophoresis of mouse tail samples. B: Protein stained 
gel (Comassie stained, left) and Western blot (with anti-CHAD, right) of 
cartilages and liver as a control of non-specific reactions. Different cartilages 
were extracted with 4M GuHCl, proteins precipitated with ethanol and 
electrophoresed on 4-16% SDS-PAGE. The lanes represent extracts of null    
(-/-) and WT (+/+) mice: 1. trachea (-/-); 2. nasal cartilage (-/-); 3. knee 
cartilage (-/-); 4. trachea (+/+); 5. nasal cartilage (+/+); 6. knee cartilage (+/+); 
7. liver (+/+); 8. recombinant CHAD.  
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3.2 RADIOGRAPHIC AND BIOMECHANICAL ANALYSES  
3.2.1 Dual X-ray absorptiometry (DXA) 
In paper I, BMD was measured in the right tibial diaphysis prior to fracture. 
Two, 3 and 6 weeks after fracture, BMD was measured in vivo in the fracture 
area, tibial and femoral diaphysis, femoral neck and the lower lumbal vertebrae. 
For the fractured tibia, BMD of the extracted intramedullary nail was measured 
and the value subtracted from the in vivo BMD values.  
3.2.2 Micro computer tomography  
In paper IV, we measured total length of femur, cortical and trabecular thickness, 
trabecular separation, bone volume and porosity, trabecular connectivity as well 
as degree of anisotropy and structure model index in mice aged 5 days, 3 weeks 
and 4 months by micro computer tomography.   
3.2.3 Three-point cantilever bending test 
In paper I, biomechanical properties of the fracture callus as well as the femoral 
neck were examined ex vivo using a three-point cantilever bending test. Although 
originally developed for testing of femoral shaft, the mechanical test has later 
been modified for testing of tibial shaft as well as the femoral neck (109).  
 
 
3.3 BONE HISTOMORPHOMETRY  
In general, tissues were fixed by transcardial in vivo perfusion, dehydrated and 
embedded in resin or paraffin. Both sections of intact calcified bone stained with 
trichrome and sections of decalcified bone stained with toluidine blue were used. 
The sampling hierarchy was designed in pilot analyses using cumulative mean 
plots for deciding sample size at each level below the animal level. At each level 
Figure 3.2. Three-point cantilever 
bending – applied forces 
The measured moment (Ta) equals the 
moment required to bend the distal tibia 
ventrally (Pb). Thus, the applied force (T) 
is directly proportional to bending 
moment (Pb).a = disc radius (2). 
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systematic random sampling was performed on coded material. In paper I, total 
outer diameter, cortical thickness and cortical area for the tibial and femoral 
diaphyses were estimated along with trabecular bone volume according to 
stereological principles with point counting as the main method (110). In paper 
IV, mean height of the epiphyseal growth plate was calculated from 
measurements along 10 randomly placed vertical arbitrary lines. The relative 
zone distribution of the epiphyseal growth plate (111)) was estimated on 
longitudinal sections through the distal femur. Finally, osteoid surface in the 
proximal tibial metaphysis was estimated using the linear intercept method (110). 
 
3.4 GENE EXPRESSION ANALYSES 
3.4.1 In situ hybridization 
Total RNA was reverse transcribed into cDNA, and gene sequences of interest 
were amplified from cDNA or directly from IMAGE clones by conventional 
PCR, using oligonucleotide primers. The sequences were subsequently cloned 
and sequenced. Digoxigenin (DIG)-conjugated complementary RNA (cRNA) 
probes were synthesized to yield probes in the sense or antisense orientation. 
Hybridization was performed by modification of a previous protocol (112); in 
brief, sections of formalin-fixed paraffin-embedded tissue were dewaxed and 
proteinase K digested, post-fixed and incubated in hybridization solution 
overnight. Excess probe was rinsed off followed by RNase treatment to remove 
unbound probe. Hybridized probe was detected with a sheep anti-DIG ALP 
conjugate, followed by nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-
indolyl-phosphate as ALP substrate. Hybridization with sense probes in place of 
antisense was performed as negative controls. In paper IV, parallel light 
microscopic (LM) immunohistochemistry (IHC) was used to show that the 
protein and the gene precursor for COMP co-label. Mounted sections were 
analyzed with respect to cellular localization of mRNA. The ratio of mRNA 
positive cells to total number of cells of the same lineage on bone surfaces was 
determined using point counting on coded sections and their corresponding 
haematoxylin/eosin-stained sections.  
 
3.4.2 DNA microarrays 
In paper III, we used DNA microarray to study differently expressed genes 
between study groups. A DNA microarray consists of a solid substrate and arrays 
of probes arranged in grids. Each probe is composed of many identical copies of 
single-stranded DNAs with a specific gene sequence. We used the 
oligonucleotide-based Rat Genome 230 2.0 array (containing more than 31,000 
probe sets) from Affymetrix Gene Chip®, where probes are generated directly on 
the substrate by light-directed chemical synthesis. Isolated RNA from the bone 
samples was reverse-transcribed into cRNA, and the cDNA molecules (“targets”) 
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were labelled with fluorescent tags (biotin) and hybridized with the probes on the 
microarray. The amount of fluorescence emitted by each spot on the microarray 
will be proportional to the amount of mRNA produced by the gene with the DNA 
sequence identical to the sequence in the spot. Finally, the hybridized microarray 
was scanned in at the wave-length appropriate to the dyes used to create a value 
which represents the expression level of a gene. Specific software programs were 
used for handling and processing of the huge data sets, and the results were 
expressed as fold changes (FC), e.g. ratio of the mean signals between compared 
groups. Gene lists were generated with the criteria of p < 0.05 and FC > 2. For 
expression comparisons of the study groups, profiles were compared using paired 
t-test.  
 
3.5  PROTEIN ANALYSES -  IMMUNOHISTOCHEMISTRY 
3.5.1 Qualitative protein analysis 
In paper IV, we used a two step IHC technique based on a horseradish 
peroxidase-labelled polymer conjugated to a secondary antibody for the detection 
of COMP in sections of long bone. In brief, formalin-fixed, paraffin-embedded 
specimens were deparaffinized and rehydrated in series of alcohols. To quench 
endogenous peroxidase activity, sections were incubated with hydrogen 
peroxide. Subsequently, sections were pretreated with chondroitinase ABC in 
tris-acetate containing 1% bovine serum albumin (BSA) for antigen retrieval. 
Incubation with normal goat serum was performed to block non-specific binding 
before application of the primary antibody. The sections were then incubated 
with the labelled polymer, and staining was completed by incubation with 
diaminobenzidine (DAB+) susbstrate-chromogen which results in a brownish 
precipitate at the antigen site. The sections were finally stained with 
haematoxylin and eosin/phloxine B. COMP distribution in the epiphyseal growth 
plate was determined on coded sections using a histologic scoring system and 
compared between study groups.  
3.5.2 Quantitative protein analysis 
In general, bone tissues for transmission electronmicroscopic (TEM) IHC were 
fixed by transcardial in vivo perfusion, further fixed in PF or a mixture of 
PF/glutaraldehyde. After decalcification and dehydration in alcohols during 
progressive lowering of the temperature, tissue blocks were embedded in an 
acrylic resin at low temperature. In paper II, some tissue sections were stabilized 
by high pressure freezing (HPF) followed by freeze substitution (FS); after 
cervical dislocation of the animals, dissected tissues were subjected to ultrarapid 
cooling by liquid nitrogen during increasing pressure in a high pressure freezer, 
which physically vitrifies tissue water without significant formation of ice 
crystals. By this procedure ultrastructural artefacts which may develop during 
chemical fixation are avoided (113) and the cell morphology is kept closer to its 
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living state because soluble cell constituents are maintained (114). Subsequent 
FS allows dehydration of the frozen samples before resin-embedding at -25°C 
and was performed with increasing concentrations of methanol.  
 
 
 
The sampling hierarchy was designed based on previous experience with similar 
analyses using cumulative mean plots for deciding sample size at each level 
below the animal level (115). Ultrathin sections were cut and mounted on 
formvar-coated nickel grids. In paper II, some sections were subjected to antigen 
retrieval by heating in citrate buffer. Immunostaining were performed by 
overnight incubations with the primary antibody reagents, before incubation with 
protein A conjugated to 10 nm gold particles. Normal rabbit IgG was used in 
place of the primary antibodies as negative controls. Before examination, 
sections were contrasted with uranyl acetate and lead citrate. Electron 
micrographs of coded sections were sampled in predetermined compartments 
(which were identified in digital pictures at a final magnification of x 49,000) 
and regions of interests (ROIs) were drawn by freehand according to the 
structural limits. After background smoothing and global intensity thresholding, 
particles occurring within the area of the ROI were counted, and the particle 
density (particles/µm2) estimated using a semi-automatic image analysis software 
program. The mean particle density for each of the predetermined 
sub/extracellularly compartments was calculated for each animal and used for 
Figure 3.3: Principles of immunolabelling  
An ultrathin section placed on a grid is incubated with primary antibodies (1) 
against the antigen under study. Gold conjugated protein A (2) binds to a 
single binding site on the Fc part of the primary antibody and can be 
visualized in the electron microscope. Figure from (1). 
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statistical comparison of gold labelling density in the compartments between the 
study groups.  
 
3.6 STATISTICAL METHODS 
All data are presented as means and standard deviations, and standard statistical 
methods were used, i.e. student’s t-test, one-way analysis of variance (ANOVA) 
and multivariate analysis of variance (MANOVA). The level of significance was 
set to 0.05. All analyses were calculated in SPSS for Windows.  
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4 SUMMARY OF RESULTS 
4. 1 PAPER I  
Experimental osteoporosis induced by ovariectomy and vitamin D deficiency 
does not markedly affect fracture healing in rats  
Melhus G*, Solberg LB*, Dimmen S, Madsen JE, Nordsletten L, Reinholt FP  
*Contributed equally to the study 
 
The question of whether fracture healing and mechanical properties of the callus 
are influenced by postmenopausal osteoporosis is still not settled. 72 female 
Wistar rats were randomized into two groups: OVX and vitamin D3-deficient diet 
(OVX-D group) or sham operation and normal rat chow (sham group). After 12 
weeks, a closed unilateral tibial midshaft fracture was performed and fixed with 
an intramedullary nail. Bone loss and callus formation were monitored with 
DXA; serum levels of estradiol and vitamin D were measured and 
histomorphometric analyses were performed. Mechanical properties of callus, 
tibia, femoral shaft, and femoral neck were examined in 3-point cantilever 
bending 6 weeks after fracture. The OVX-D group showed reduced BMD in the 
spine and femoral neck, and reduced trabecular bone volume in the femoral head. 
There were no differences in BMD and mechanical properties of callus between 
the groups. Except for reduced stiffness of the right femoral neck in the OVX-D 
group, no differences in the mechanical strength of long bones were detected.  
 
Conclusion of the study: The results suggest that systemic effects of estrogen and 
vitamin D deficiency are not crucial for fracture healing or mechanical properties 
of the callus. 
 
 
4.2 PAPER II  
  
Heat-induced retrieval of immunogold labelling for nucleobindin and 
osteoadherin from Lowicryl sections of bone. 
Solberg LB*, Melhus G*, Brorson SH, Wendel M, Reinholt FP.   
*Contributed equally to the study 
 
The preparation, fixation and embedding of bone tissue enabling 
electronmicroscopic studies of tissue distribution of proteins complicates and 
may distort localization of antigens by antibodies. Thus, in order to investigate 
whether heating of bone sections may enhance signalling intensity; the 
immunogold signal for two bone proteins (NUC and OSAD) was compared in 
retrieved and non-retrieved sections of PF-fixed normal rat bone. As an 
additional experiment, the effect of antigen retrieval (for NUC) in sections of 
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tissue primary stabilized by high pressure freezing with subsequent freeze 
substitution (HPF-FS) was studied. Finally, the tissue distribution patterns of 
NUC labeling were compared in non-retrieved HPF-FS sections to that of 
retrieved and non-retrieved PF-fixed sections. Antigen retrieval in Lowicryl 
sections of PF-fixed tissues showed significantly enhanced labeling intensity for 
both proteins in all compartments where they are known to occur. Retrieved PF-
fixed sections showed only minor ultrastructural differences compared to non-
retrieved ones. Retrieval of HPF-FS sections exhibited no enhancement of 
labeling but rather a slight reduction, which was significant in the cytoplasm and 
in cartilage. Furthermore, striking ultrastructural differences were observed in 
retrieved HPF-FS sections compared to non-retrieved ones with loss of 
coherence and structure in sections subjected to heating. Comparison of the 
distribution patterns of Nuc in the sections of PF-fixed and HPF-FS tissues 
showed discrepancy in most compartments.  
 
Conclusion of the study: Antigen retrieval by heating Lowicryl sections of PF-
fixed tissues significantly enhances immunogold labeling in all cell 
compartments where the bone proteins are known to occur. However, the 
procedure may distort the tissue distribution pattern of bone proteins. 
 
4.3 PAPER III  
Gene expression and distribution of key bone remodelling markers in the 
callus of estrogen-deficient vitamin D depleted rats 
Melhus G, Brorson SH, Baekkevold ES, Andersson G, Jemtland R, Reinholt FP  
 
To investigate whether postmenopausal osteoporosis influences the gene 
expression and molecular composition of the ECM in the fracture callus, we 
investigated global gene expression, mRNA synthesis and ultrastructural protein 
distribution in fracture callus after 3 and 6 weeks of healing for four NCPs in the 
animal model used in paper I.  
 
Conclusion of the study: Several genes are differently regulated in osteoporosis 
induced by OVX and vitamin D depletion, mostly in an early stage and the 
majority in an increased fashion, although no genes encoding NCPs with known 
function in bone metabolism were differently expressed. On the background of 
only minor differences in the synthesis and protein expression of OPN, BSP, 
TRAP and CTK in callus between OVX-D and sham treated animals, our results 
suggest that the molecular composition of the fracture callus is not markedly 
skewed in osteoporosis. 
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4.4 PAPER IV  
Chondroadherin-deficient mice present a distinct skeletal phenotype 
Melhus G*, Hessle L*, Wenglen C, Brorson SH, Petzold C, Baekkevold ES, 
Heinegard D, Reinholt FP  
* Contributed equally to the study 
 
CHAD, a cartilage matrix protein belonging to the SLRP family, possesses cell 
binding properties and is suggested to play a role in cartilage homeostasis. We 
have generated CHAD null mice to study the role of CHAD in vivo. These mice 
show no gross anatomical abnormalities, but exhibit a distinct skeletal phenotype 
with disturbances of the epiphyseal growth plate, alteration of trabecular and 
cortical bone parameters with lack of the sex- specific differences seen in WT 
mice, as well as markedly decreased number of BSP expressing cells in the 
proximal tibial metaphysis. However, the CHAD null mice presented unaltered 
expression of OPN, TRAP, CTK and COMP, and normal immunostaining for the 
latter in the growth plate. Furthermore, ultrastructural analysis showed unaltered 
protein distribution pattern of BSP and OPN in bone.  
 
Conclusion of the study: These results demonstrate an important role for CHAD 
in both bone and cartilage homeostasis, clearly visualized by the distinct bone 
phenotype of CHAD null mice.  
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5 GENERAL DISCUSSION 
5.1 METHODS  
The animal models are discussed in the respective papers, and the applied 
methods are in general well established. However, some aspects are commented 
upon below.  
 
5.1.1 The model of fracture healing in postmenopausal osteoporosis  
The OVX rat is the most widely used laboratory animal model for osteoporosis 
research. The model is approved by the FDA as clinically relevant in the study of 
postmenopausal osteoporosis (116). The skeletal changes in the OVX rat share 
several characteristics to postmenopausal osteoporosis, e.g. bone resorption 
exceeding bone formation, predominant trabecular bone loss and similar 
response to treatment with drugs like bisphosphonates, estrogen, PTH and 
calcitonin (117-118). OVX in rodents does not, however, regularly lead to 
weakening of cortical bone (119-121) and the frequent low-energy fractures 
occurring in humans (122) are absent (118).  Vitamin D deficiency is very 
common among the elderly as well as in postmenopausal and osteoporotic 
women and has been implicated in the development of osteoporosis and ensuing 
risk of fragility fractures (for references, see (123)). In studies presented in paper 
I and III, OVX and vitamin D depletion were combined to induce osteoporosis, 
on the background of the findings by Kaastad et al. showing a significant 
weakening of the femoral neck in this model (121). Therefore, we considered this 
model to be particularly relevant in the study of fracture healing in 
postmenopausal osteoporosis. Although most postmenopausal women with 
osteoporotic fractures are elderly, advancing age per se is associated with 
impaired fracture healing (124-127). Therefore, to exclude age as a confounding 
factor, young rats were used.  
As expected, loss of bone in trabecular areas was found 3 months after 
OVX/introduction of vitamin D-deficient diet, as well as decreased bending 
stiffness of the femoral neck compared to controls. Absence of detectable bone 
loss and unchanged mechanical function in cortical bone are in line with previous 
reports; cortical bone loss does occur but slowly and to a lesser extent 
(117,121,128). However, in spite of cortical thinning,  mechanical strength may 
be preserved as a result of periosteal apposition and altered bone geometry (129). 
No such geometric compensation was detected in our model.  
There are some limitations using the OVX rat as a model for human 
osteoporosis, e.g. the lack of the Haversian system in cortical bone, the 
maintained osteoblast function during the late stages of estrogen deficiency and 
the absence of BMU-based remodelling in young rats (130), as well as the 
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seeming life-long modelling of bones rather than remodelling which differ from 
that in human adulthood (131-132).  
We used a diaphyseal fracture healing model previously shown to provide stable 
fractures by intramedullary nailing. Mechanical properties were studied in a 3-
point cantilever bending test that has been demonstrated to provide standardized 
loading until failure and reproducible results (133-135). Intramedullary nailing 
gives flexible fixation, thereby resulting in indirect healing characterized by 
periosteal callus formation and endochondral bone formation. However, 6 weeks 
after fracture in our series, there was a substantial inter-individual variation with 
respect to macroscopic callus size and morphologic composition accompanied by 
a relatively high incidence of non-unions.  
The indirect healing of fractures is strongly influenced by the amount of 
interfragmentary movement induced by the load of the fracture site and the 
stability of the fracture fixation. Thus, a likely explanation for the heterogeneous 
fracture calluses is that the fractures have been subjected to various degrees of 
mechanical stability, and non-unions may have occurred as a result of suboptimal 
positioning of the nail, thereby allowing excessive motion at the fracture site. 
However, since most non-unions presented little or no visible callus formation, 
non-unions could also be due to a too rigid nail. Actually, in vivo studies have 
shown stress shielding from the use of rigid internal fixators (136-137) and 
refractures after removal of these (138). However, complete union in this fracture 
model using the same type of nail has been reported (135). Furthermore, a too 
rigid fixation cannot explain the heterogeneity in those animals that achieved 
union.  
After exclusion of non-unions, the sample size for mechanical testing was still 
considered sufficient to detect a clinically relevant difference in mechanical 
properties of 20% between the groups. However, no significant differences were 
observed, but substantially larger standard deviations (in the range of 29% - 
55%) were noted for the fractured tibias compared to the intact contralateral 
controls. This may indicate that the variation was due to inter-individual 
differences in fracture healing/callus, rather than the bending test itself.  
Heterogeneity in the callus sample may also have influenced the results reported 
in paper III. The recruitment of mesenchymal stem cells (MSCs) is a key 
component in the healing process, and mechanical stimulation is an important 
factor in determining their cellular fate, i.e. whether they differentiate into 
osteoblasts, chondrocytes, adipocytes, fibroblasts or myoblasts (139-140). 
Mechanical stimulation promotes chondrogenetic differentiation and expression 
of cartilage-related genes (141), and thus, substantial variation in the ratio of 
cartilage- and bone specific gene expression may have contributed to large 
standard deviations in the genetic and molecular results. Another aspect of the 
model is fracture localization; we (as most other authors) examined healing of a 
diaphyseal fracture since this is easy to establish and can be fixed in a 
standardized manner. However, long bones are more predisposed to osteoporotic 
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fractures at the metaphyses rather than at the diaphyses (95,142), and the 
mechanisms of metaphyseal healing are different from those of diaphyseal bone: 
In general, diaphyseal fractures heal indirectly with visible periosteal callus 
formation, whereas metaphyseal fractures usually heal directly with endosteal 
bone bridging by micro-callus and without significant periosteal callus 
formation. Furthermore, the periosteum, which plays a central role during 
fracture healing, displays site-specific differences in long bones (143). However, 
while trabecular and cortical bone are architecturally different, they are similar at 
the molecular and biochemical level. The fracture localization is therefore of 
most relevant for the results in paper I.   
 
 
5.1.2 The applied methods   
DNA microarrays  
Several studies using a “gene-by-gene” approach to identify the temporal 
expression of gene(s) of interest during fracture healing (144-145), in 
osteoporosis (146) and in fracture healing in osteoporosis (147) have been 
published. Although this approach shows the spatial distribution of expression, it 
is not useful in isolating novel genes involved in these processes. Such data can 
be obtained through the microarray technique. This is a powerful tool to unravel 
so-far unknown genes involved in osteoporotic fracture healing by allowing the 
co-ordinated study of the expression of thousands of genes.  In paper III, total 
fracture callus RNA at two different time points was collected, and pooled RNA 
was used for expression-profiling studies. Although no known NCPs were 
differently expressed, a variety of genes were found to be differentially regulated 
in the OVX-D animals.  Limitations of our microarray approach include the 
small number of time points evaluated, the limited sample size (due to ethical 
considerations and prohibitive costs of the technology), and mixing of the callus 
RNA samples in each group (due to low levels of RNA in adult rat bone). Due to 
the latter, inter-individual differences or differences related to bone- and 
cartilage-specific genes in the callus are not detected, which is of particular 
relevance in light of the observed morphological heterogeneity of the calluses. 
Finally, one cannot conclude that changes in mRNA levels by necessity mean 
parallel changes in protein secretion and tissue distribution as these parameters 
are regulated also by other mechanisms. 
 
Immunoelectron microscopy and antigen retrieval (paper II) 
The aim of TEM IHC is to localize molecules in biological samples at a spatial 
resolution that cannot be achieved by LM IHC. Fixation/immobilization of 
specimens can modify both tissue morphology and antigenicity from that of the 
living state, and thus, a central issue is to preserve the epitope of interest while 
minimizing the loss of ultrastructural detail. Preparation of tissues for 
immunogold labelling can be achieved either by 1) chemical fixation with 
5 GENERAL DISCUSSION 
 46 
aldehyde followed by progressive dehydration and embedding at low temperature 
(148), 2) brief chemical fixation with aldehyde followed by cryofixation and 
cryosectioning (149), or 3) cryofixation techniques followed by FS and 
embedding at low temperatures (150). HPF followed by FS is considered to 
provide the best compromise between preservation of ultrastructural morphology 
and antigenicity (151-155). However, the HPF-FS technique requires specialized 
and expensive equipment not available in most laboratories, and the capacity to 
freeze large series of samples uniformly is limited. Thus, chemical fixation 
followed by low temperature embedding is often the technique of choice in TEM 
IHC, and chemical fixation using cross-linking reagents such as PF with or 
without small concentrations of glutaraldehyde is frequently used for TEM IHC 
(for references, see (156)). However, effective chemical fixatives that preserve 
morphology frequently destroy biological activities and/or mask antigens, and 
consequently, different antigen retrieval techniques have been developed both for 
LM and TEM IHC (for references, see (157)).  
Heat-induced antigen retrieval is one of the most widely used techniques for 
formalin-fixed paraffin-embedded tissue, but is also applicable on frozen sections 
(158) and sections prepared for immunoelectron microscopy (159-162). The 
main mechanism is believed to be cleavage of the intra- and intermolecular 
crosslinks (i.e. methylene bridges) induced with formaldehyde (163-165). In 
paper II, we used the HPF-FS technique as a gold standard, to evaluate whether 
antigen retrieval by heating sections of PF-fixed tissue embedded in the acrylic 
resin Lowicryl HM23 could increase immunogold labelling for two NCPs in 
bone tissue without markedly affecting ultrastructural morphology. When the 
sections were heated in citrate buffer at 95°C for 15 min, significant 
enhancement of immunogold labelling of both NCPs was observed. Surprisingly, 
compared to the distribution patterns in HPF-FS sections, retrieved sections of 
PF-fixed tissue showed alternations in the relative protein distribution between 
sub- and extracellular compartments. To our knowledge such an effect of antigen 
retrieval by heating has previously not been reported. The results may also have 
implications for results of LM IHC following antigen retrieval by heat. 
Taken together, our results suggest that although high-temperature heating may 
disclose antigens in bone tissue fixed by PF and embedded in acrylic resin, heat 
may distort the native protein distribution and therefore should be used with 
caution in studies of molecular distribution at the ultrastructural level. Our results 
support more recent data recommending HPF-FS in TEM IHC when the 
preservation of tissue ultrastructure in its most native state is the goal (166-167) .  
 
Semi-quantitative immunogold analysis 
Immunogold TEM IHC is a powerful method for the detection and localization 
of tissue antigens at the ultrastructural level and allows quantisation due to the 
electron dense nature of the gold particles and to the fact that only epitopes at the 
surface of the section are detected (for references, see (168)). Robust tools for 
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specimen sampling, stereological estimation and statistical evaluation of 
subcellular gold-labelling distribution are important design features and allow 
reproducible results (169). Multistage random sampling is required due to the 
small specimen size, and guarantees every part of the object under study an equal 
chance of being sampled (110). The labelling density (number of gold particles 
per area unit (170)) in different compartments/ ROIs can be compared directly 
using t-tests (171) or when the relative protein distribution in several 
compartments  are compared between groups such as in paper II and III, 
multivariate analysis of variance (MANOVA) is the statistical tool of choice (Jon 
Michael Gran, Department of Biostatistics, Medical Faculty, University of Oslo, 
personal communication). However, the high magnification required to identify 
gold particles and compartments by shape and size, contributes to the fact that 
the collection of information on overall antigen distribution is extremely time-
consuming. Therefore, various semi-automated image analysis software 
programs have been developed for fast and automatic quantification of gold 
particles. Despite the effectiveness and the advantages of automated particle 
detection, its quality depends on the operator. Due to simplistic particle detection 
and quality control algorithms, small, false positive particles may easily go 
unnoticed unless the operator is aware of this possibility and has been duly 
trained to optimize threshold levels.  
  
5.2 RESULTS 
 
5.2.1 Fracture healing in osteoporosis (paper I and III)  
Osteoporosis and the associated changes in bone metabolism may influence the 
outcome of fracture healing. However, clinical studies have failed to demonstrate 
a direct link between the hormone deficiency and the decrease in bone 
regeneration, as the endocrine status and possible co-morbidities may constitute a 
considerable bias. To date, no clinical studies reporting impaired/delayed healing 
in osteoporotic patients compared to age-matched controls have been published. 
Thus, the current dogma of impaired fracture healing in postmenopausal women 
is primarily based on increased failure rates of fixation devices (172-173), and 
experimental studies using the OVX rat model (127,174-179). Although delay in 
bone healing has been reported in OVX rats at certain stages of fracture repair 
(127,174,177-179), other published data suggest that some phases of fracture 
repair in OVX rats are relatively unimpaired. Moreover, the effects of estrogen 
depletion as well as of other important hormones involved in mineral metabolism 
are not significantly detrimental to bone regeneration (174-176).  
 
Recent experimental data suggest relatively unaltered healing capacity 
Bone density and bone quality, which encompass the structural and material 
properties of bone, are both important for bone strength (180-181) and the proper 
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biological functioning of bone (182-183). Bone quality is determined by the 
characteristic of the matrix (material quality) and the structural characteristics of 
bone. Material quality plays an important role in the reinforcement of bone 
strength. 
 
In paper I we show that fracture healing and mechanical properties of callus in 
OVX-D rats are not markedly influenced by the osteoporotic condition. Several 
previous studies support our observations by reporting unaltered mechanical 
properties of callus in OVX rats at certain time points after fracture; e.g. Wheeler 
et al. (175) report no differences after 4 and 6 weeks, and Cao et al. (176) find no 
changes after 6 and 16 weeks in OVX rats; their findings do, however, suggest an 
accelerated and favourable callus remodelling. Furthermore, Kubo et al. (174) 
report almost identical healing in OVX and controls after 6 weeks but apparent 
histological osteoporotic changes and decreased BMD in callus after 12 weeks.  
 
However, other studies suggest impaired healing and mechanical properties, e.g. 
Hao et al. report decreased mineralization and not well connected microstructure 
in callus after 4, 8, and 12 weeks, accompanied by impaired mechanical 
properties at the end point, as compared to controls (184). Yet another study, 
using infrared spectroscopic imaging to identify changes in fracture callus, shows 
an apparent decrease in mineral to matrix ratio and collagen cross-linking in 
early stages of fracture healing in OVX rats, but with a gradual normalization 
until similar values to those of estrogen-treated OVX rats (controls) were 
obtained after 12 weeks (185), suggesting a OVX-related delay only in early 
stages of the healing process. In support of the latter, normal enzymatic cross-
linking of collagens in callus at the same time point (i.e. 12 weeks after fracture) 
is recently reported in OVX rats (186), and may be a determinant of the material 
property of bone (187-188). Thus, as a whole, disparities are found in previous 
experimental data on fracture repair in osteoporotic bone.   
 
Interestingly, most recently published studies comparing fracture healing in OVX 
rats and controls provide new evidence for unaltered healing capacity; Shi et al. 
(189) report indifferent healing with maintenance of mechanical properties of 
femoral fractures after 2, 3 and 8 weeks, while  Saito et al. (186) report only 
minor differences after 12 weeks’ healing of a femoral osteotomy in OVX rats. 
Yet another study finds no significant differences in callus formation and 
mechanical properties in OVX rats as compared to controls 5 weeks after a 
metaphyseal tibia osteotomy, although estrogen prophylaxis in the healing period 
significantly improved fracture healing in the OVX group (190). However, Ding 
et al. suggest that OVX influences fracture healing; these authors report 
decreased vascularisation and lower BMD of callus in OVX rats 1, 2, 4 and 8 
weeks after fracture with some influence on mechanical properties after 2 and 8 
weeks (i.e. lower ultimate stress but unaltered energy to ultimate load and no 
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differences in Young’s modulus), whereas micro-CT revealed differences in 
callus composition only at the two early time points (191).  
 
On the other hand, also recent fracture studies in transgenic mice support our 
results; Egermann et al. (192) investigated fracture healing in senile osteoporosis 
using SAMP6 mice, a model of senile osteoporosis which display a bone 
phenotype with reduced trabecular bone volume (193), decreased bone strength 
(194) and reduced areal BMD (195). The bone marrow-derived MSCs from these 
mice show a reduced capacity for osteoblast differentiation and increased 
adipogenesis (196-198) similar to the reported alternations of MSCs from 
postmenopausal women (199-200). The important role of MSCs in fracture 
repair is well documented (67,201-202). However, SAMP6 mice exhibited 
unaltered healing capacity despite the impaired differentiation capacity of BMCs, 
thus simultaneously calling into question the role of bone marrow-derived MSCs 
in the repair process and supporting our demonstration of unaffected healing 
under an osteoporotic condition.  
 
Taken together, recent findings mainly support our results as well as clinical 
observations that, although fracture fixation is difficult in osteoporosis, the 
healing potential seems to be relatively unchanged.  
 
The impact of vitamin D deficiency on fracture healing 
Prolonged vitamin D deficiency has several skeletal consequences in humans, 
and may induce decreased bone formation and mineralization, (rickets in children 
and osteomalacia in adults) or osteopenia/ osteoporosis. Severe vitamin D 
deficiency results in decreased serum concentration of ionized calcium, a rise in 
PTH, and calcium malabsorption (203). However, vitamin D insufficiency (low 
serum vitamin D without rickets or osteomalacia) does not per se cause 
malabsorption of calcium (204), but is deleterious to bone because it is 
associated with secondary hyperparathyroidism and signs of increased bone 
resorption (205). Vitamin D exerts its effects through the vitamin D receptor 
(VDR). The principal action of the VDR in skeletal growth, maturation, and 
remodelling concerns its role in intestinal calcium absorption (206). Although 
human trabecular bone cells respond in vitro to exogenous 1,25(OH)2D3 by 
increasing expression of bone matrix genes such as osteocalcin and BSP (207) 
and mature osteoblasts express VDRs, studies of vitamin D-deficient rats have 
failed to demonstrate significant differences in the bone content of several matrix 
proteins, including osteocalcin, relative to those in normal rats (208). These 
observations raise questions regarding the importance of vitamin D in adult bone 
metabolism.  On the other hand, administration of active vitamin D analogues do 
seem to have a positive effect on OVX-induced bone loss by inhibiting bone 
resorption and maintaining bone formation (209-210) 
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Neither the effect of vitamin D nor its analogues on fracture healing have been 
fully established, although vitamin D deficiency has been associated with 
increased risk of non-unions (211). The administration of vitamin D during 
fracture healing in normal and OVX rats have shown conflicting results 
(186,212). To our knowledge, no previous studies have investigated the impact 
of vitamin D deficiency on fracture healing in OVX rats. All OVX-D rats 
developed vitamin D deficiency in paper I; 94% showed undetectable levels of 
25(OH)D. Previous studies report that when vitamin D-deficient animals are kept 
normocalemic by experimental or dietary means, no osteomalacia occurs (213) 
and corroborate that bone in vitamin D deficient rats may be normal when the 
mineral supply is adequate (213). Thus, due to normal dietary calcium content, 
the additional effect of vitamin D deficiency may have been minor in our series.  
 
Molecular matrix composition in osteoporotic fracture healing 
Until recently there has been relatively limited evidence for altered molecular 
matrix composition in human osteoporotic bone (214-216), although increased 
expression of cytokines such as IL1, IL6 and RANKL has been reported 
(146,217). However, several genes encoding NCPs and other molecules involved 
in bone metabolism, including OPN, BSP, CTK and TRAP, were reported to be 
differentially expressed in iliac crest biopsies from postmenopausal women by 
micro array (Reppe et al., unpublished observations).  
In addition, previous experimental data have shown increased mRNA levels of 
osteoblast-related genes including OPN (218), and augmented number of OPN-
expressing osteocytes in bones of OVX rats (219). Furthermore, Hatano et al. 
investigated estrogen-regulated genes during fracture healing in rats using  
microarray and found 52 genes to be downregulated by OVX and restored with 
estrogen, out of which differential mRNA expression was confirmed for 4 of 
these by qPCR (i.e. collagen type II, extracellular superoxide dismutase, 
urokinase-type plasminogen activator and ptk-3) (220).  
Taken together, we therefore hypothesized that that the molecular composition of 
the callus in osteoporosis could be skewed with respect to matrix molecules 
involved in bone remodelling.  
 
However, in paper III we demonstrate, first, that OVX-D rats present no altered 
expression of genes encoding neither collagens nor NCPs, and second, only 
minor quantitative differences with respect to mRNA expressing cells and 
ultrastructural protein distribution of OPN, BSP, TRAP and CTK compared to 
controls, thus indicating basically unaltered composition of callus in 
experimental osteoporosis.  
Among the latter molecules, OPN and BSP are particularly interesting in the 
aspects of fracture repair in vitamin D-deficient osteoporotic bone: OPN plays a 
role in OVX-related bone loss (221) as well as in fracture healing (222) by 
affecting angiogenesis, callus formation and mechanical strength of callus in 
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early stages of healing while facilitating later stages of remodelling and ECM 
organization. BSP, but not OPN, plays a role in primary bone formation and 
mineralization of newly formed bone during cortical bone healing (223). Both 
OPN and BSP are under the influence of vitamin D3, which exerts different 
transcriptional effects on these genes in vitro (stimulates OPN (224), suppresses 
BSP (225-226)) as well as in vivo (transgenic vitamin D3-deficient mice present 
increased BSP and decreased OPN expression (227)).  
 
However, the observed lack of altered regulation of these genes in the OVX-D 
group, supported by ISH and TEM IHC findings may question the importance of 
vitamin D and estrogen in regulation of these NCPs in the fracture healing 
process. In support of our findings, unaltered expression of osteocalcin, IGF-1, 
collagen 1α1 and TRAP have recently been reported in the callus of OVX rats 
compared to controls (147). Thus, although some data indicate altered molecular 
callus composition, taken together with the results of paper I, the seemingly 
unaltered NCP composition of the fracture callus in experimental osteoporosis 
supports the hypothesis that the fracture healing process is not markedly 
influenced by OVX in rodents.  
 
On the other hand, recent clinical data indicate altered expression of genes 
encoding matrix molecules in intact bone from postmenopausal osteoporotic 
women; a targeted gene expression study show downregulation of genes for 
ALP, COL1A1, MMP2, MMP9 and MMP13, platelet-derived growth factor 
alpha polypeptide (PDGFA), nuclear factor of kappa light polypeptide (NFKB1) 
and upregulation of thrombospondin receptor (CD36), and twist homolog 2 
(TWIST2) (228). Another study comprehensively characterizing differential gene 
expression in human osteoporosis (229), reported alterations in several genes 
regulating osteoclastogenesis and bone resorption, in particular TREM-2, CCL2, 
RANK and IL-6 (identified in previous studies (217)), thereby confirming that 
genes responsible for osteoblast maturation are differentially expressed, in 
particular CTSB (cathepsin B), TGFB1(TGFβ1) (230-231), but also SPP1 (OPN) 
and CTGF (connective tissue growth factor). Moreover, microarray analysis of 
human osteoporotic osteoblasts has revealed 352 potentially differentially 
regulated genes, out of which four new candidate-genes for osteoporosis were 
verified in bone by qPCR; two cytokines (pleiotrophin (PTN) and chemokine (C-
X-C motif) ligand 2 (CXCL2)), collagen type XV alpha 1 (COL15A1) and BSP 
(IBSP) (232). Taken together, these studies indicate changes in bone composition 
at the tissue level, and consequently, altered quality of inorganic and organic 
matrix in human postmenopausal osteoporosis.  
 
However, the fact that several gene profiling studies on human osteoporotic bone 
have disclosed different expression of genes, and thus implicated these in the 
pathogenesis of osteoporosis, does not necessarily mean that the mechanisms of 
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response to a certain stimulus such as fracture differ from those of healthy bone; 
the bone trauma and the subsequent repair response may override the 
osteoporotic condition, allowing important genes to be expressed at a sufficient 
level to complete the repair process in a physiological manner.  
 
The role of FGF23 and IL-17RA  
The fracture healing process is influenced by a variety of molecules other than 
NCPs which could possibly contribute to altered healing capacity. However, out 
of the variety of genes encoding cytokines, growth factors and receptors involved 
in fracture healing and bone metabolism, only fibroblast growth factor 
23(FGF23) and interleukin-17 receptor A (IL-17RA) turned out to be differently 
regulated in the OVX-D group, being down- and upregulated at 3 weeks, 
respectively. FGF23, a phosphaturic hormone, is part of a newly discovered 
hormonal bone – parathyroid – kidney axis, which is modulated by PTH, vitamin 
D and phosphate levels. Recent studies show that 1,25(OH)2D3 regulates FGF23 
production through VDRE in the FGF23 promoter (233), being a potent 
stimulator of FGF23 (234), and that osteoblastic bone formation is a potent 
modulator of FGF23 production and release into the circulation (235). 
Interestingly, FGF23 has recently been suggested as a putative marker of fracture 
healing, and decreased mRNA expression is associated with delayed healing in 
ovine bone (236). Thus, reduced FGF23 expression in the early phase of fracture 
healing in the OVX-D group may reflect reduced osteoblastic activity and, 
consequently, impaired fracture healing. It should be noted that we did not test 
mechanical properties of callus at this time point.  
IL-17A (also known as IL-17) is a proinflammatory cytokine similar to TNFα 
(237) and may be involved in bone turnover (238). IL-17 is produced by a subset 
of Th lymphocytes (Th17 cells) (239) and acts upstream of IL-6 and synergize 
with TNFα to promote inflammation and bone turnover in rheumatoid arthritis 
(240). The mechanism is at least in part related to the capacity of IL-17 to 
upregulate the ratio of RANKL to OPG, thereby promoting osteoclastogenesis 
(241). On the other hand IL-17 seems to be bone-protective in certain situations; 
IL-17RA null mice exhibit more pronounced bone loss compared to WT mice 
following OVX (242). Furthermore, these authors report that IL-17 negatively 
regulates adipogenesis and subsequent leptin expression, which correlates with 
increased bone destruction during OVX. Thus, the possibility that upregulation 
of IL-17RA in OVX-D rats could represent a bone protective effect contributing 
to maintenance of callus strength, cannot be excluded. However, the potential 
role of IL-17RA needs to be further elucidated.  
 
Taken together, a reasonable explanation for largely unaltered healing capacity in 
osteoporosis is that the repair process is essential to the individual in an 
evolutionary aspect, and therefore is given priority in biological systems and 
allowed to override the osteoporotic condition. Consequently, the immediate 
5 GENERAL DISCUSSION 
 53 
repair response is strong and basically unaltered, while later remodelling of 
callus may be influenced by the disturbed coupling and by resorption exceeding 
formation.  
 
5.2.2 The role of chondroadherin in bone and cartilage (paper IV)    
CHAD, a member of the SLRP family, is highly expressed in cartilage, but also 
in other tissues such as bone and tendon. The protein interacts with both collagen 
and cells and is assumed to play a role in matrix homeostasis (for references, see 
(243)). Furthermore, CHAD was one of the differentially regulated genes in iliac 
crest biopsies from osteoporotic women, as analyzed by microarray (Reppe et al, 
unpublished observations). We have developed mice whose gene for CHAD is 
deleted. These null mice present a distinct skeletal phenotype, substantiating an 
important role for CHAD in bone and cartilage metabolism.  
 
Alternations in cortical/trabecular bone parameters 
Differences in trabecular/cortical bone parameters were first apparent at the age 
of 4 months, where the null mice presented significantly higher volumetric 
BMD, lower cortical thickness but increased trabecular thickness compared to 
WT mice. Interestingly, the normal differences in these parameters between male 
and female WT mice were absent in the null mice, indicating that CHAD is 
important in the sex-specific skeletal development. Similar observations have 
been reported in OPN knockout mice (244). 
Disturbances in the epiphyseal growth plate  
CHAD null mice presented markedly disturbances at the epiphyseal growth 
plate, with a general widening of all zones, but most pronounced in the 
proliferative zone. Previous studies show that CHAD is synthesized mainly by 
late proliferative chondrocytes in the epiphyseal growth plate, and deposited 
close to the cells in the territorial matrix (245). Due to its restricted tissue 
distribution and the apparent absence of cell spreading and growth of 
chondrocytes on CHAD-coated surfaces (246), a role in regulation of cell 
division has been suggested (245). The balance between proliferation and 
differentiation of chondrocytes is an important regulatory step controlled by 
multiple signaling molecules, including the Ihh/PTHrP feedback loop. 
Interestingly, Ihh, which is upstream in the signaling pathway of PTHrP, shows a 
similar distribution of expression to that of CHAD (247). PTHrP is regulated by 
Ihh, and the length of the proliferative zone of the growth plate is determined by 
a combination of the stimulatory effect of Ihh on chondrocyte differentiation and 
the inhibitory effect of PTHrP on hypertrophic differentiation. On the 
background of the very distinct localization around a portion of the proliferative 
chondrocytes and the observed widening of this zone in null mice, it could be 
speculated that CHAD may influence the Ihh/PTHrP feedback loop and/or 
participate in the control of chondrocyte differentiation by promoting 
hypertrophy.  
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Decreased number of cells expressing BSP mRNA 
Interestingly, a markedly reduced number of BSP mRNA-expressing cells were 
detected in the distal femur metaphysis of CHAD null mice. BSP promotes 
mineralization (248), and taken together with the slightly increased osteoid 
surface observed in null mice, this could reflect suboptimal mineralization. 
Further studies should be performed to elucidate the role of CHAD in the 
mineralization process. Ongoing work suggests that CHAD influences the 
cytokine production by osteoblastic cells, thereby reducing the production of 
osteoclast stimulatory factors such as IL-1, IL-6 and RANKL (16). The increase 
in volumetric BMD observed in null mice could be due to decreased osteoclastic 
resorption and supports this hypothesis. However, no quantitative differences 
with respect to the number of cells expressing the osteoclastic markers TRAP 
and BSP were noted.  Neither did the number of OPN and COMP mRNA-
expressing cells vary between the groups, supported by normal immunostaining 
for COMP in the territorial matrix of chondrocytes in the growth plate. Thus, the 
lack of CHAD did not induce general changes in synthesis of NCPs at the current 
detection level.   
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6 CONCLUSIONS  
 
1. The fracture healing process in experimental postmenopausal osteoporosis 
does not seem to differ markedly from that in healthy bone, neither at the 
mechanical nor at the molecular level. The role of IL-17RA and FGF23 should 
be delineated in future studies. 
 
2. Antibody retrieval by heating increases the signal intensity for NUC and 
OSAD in Lowicryl sections subjected to TEM IHC. However, the heating 
results in skewed protein distribution, and thus, the technique cannot be 
recommended in studies addressing ultrastructural protein distribution in bone 
tissues. 
 
3. CHAD plays an important role in bone and cartilage turnover in mice, 
illustrated by the observed skeletal phenotype in CHAD null mice, with 
alternations in trabecular/cortical bone parameters, widening of the epiphyseal 
growth plate and decrease in the number of BSP expressing cells.  
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7 FUTURE PERSPECTIVES 
 
7.1. Fracture healing in postmenopausal osteoporosis    
Future studies should focus on improving the OVX-D model to reduce variation 
so as to allow firmer conclusions. First, the introduction of a metaphyseal 
fracture model closer mimicking the clinical situation should be considered with 
respect to mechanical properties. Despite challenges in fixation of such fractures, 
several recent models have achieved successful stabilization (142,190). 
Secondly, the surgical technique should be optimized in order to minimize non-
unions and to obtain a more reproducible callus size. Thirdly, a proper pilot study 
should be performed using histomorphometry, micro-CT and mechanical testing 
at several time points (e.g. at 2, 4, 6, 8, 12, and 16 weeks after fracture) in order 
to determine the most relevant time points for extended analyses in a larger 
experiment. One way to establish more homogenous groups may be to start with 
a larger number of animals in the main experiment, thereby allowing 
subselection of calluses into groups according to macroscopic callus size (e.g. 
“small” and ”large” calluses). Similar macroscopic size would reduce the 
problem of “comparing apples and oranges”, i.e. calluses subjected to various 
degrees of mechanical forces during healing. By decreasing inter-individual 
variation in the sample increased power would be anticipated in the statistical 
analyses. Furthermore, microarray analyses should be performed on whole callus 
samples at the different time points to reveal candidate genes subjected to 
detailed analyses at the cellular- and molecular level (e.g. qPCR, ISH, proteomics 
and semi-quantitative TEM IHC). Detailed histomorphometrical analysis 
(including osteoblast/osteoclast surfaces and osteoid measurements) should be 
performed to investigate cell activity and mineralization. For dynamic 
histomorphometry, double tetracycline labelling (intraperitoneal injection in vivo 
at two time points) is required.   
 
The next step includes further analyses of the differentially regulated genes 
(encoding FGF23 and IL17RA) in paper III with suggested/potential roles in 
fracture healing/osteoporosis, qPCR to confirm altered expression, ISH to detect 
mRNA expressing cells in the callus and LM and TEM IHC to determine 
differences in localization and quantization at the protein level.   
 
To extend our observations in paper I and III, a detailed supplementary 
histomorphometric analysis of callus after 3 and 6 weeks of healing is in progress 
and will be included in the revised manuscript (paper III).   
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7.2. The role of Chondroadherin in bone and cartilage metabolism 
To extend our observations of the skeletal phenotype of CHAD null mice 
mechanical testing of femurs from 4 months old mice should be performed to 
delineate the functional impact of the findings by micro-CT. Furthermore, the 
histomorphometric analyses should be extended by including 
osteoblast/osteoclast parameters as well as osteoid surface and thickness 
measurements. During the experiment, double tetracycline labelling should be 
performed, which enables estimation of dynamic bone remodelling 
parameters/mineralization, e.g. to measure mineral apposition rate and bone 
formation rate and allowing calculation of osteoid mineralization and osteoid 
maturation time. 
To confirm reduced BSP expression in osteoblasts, qPCR should be performed. 
Furthermore, proteomics should be included in future experiments to confirm the 
presence (quantity) of proteins as well as to identify compensatory alternations of 
protein concentrations in the null mice.  In addition, in vitro osteoclast/osteoblast 
differentiation using mouse BMCs cultures should be evaluated as a 
supplementary approach. 
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ABSTRACT  
Purpose: An experimental rat model was used to test the hypothesis that in 
osteoporosis (OP) the molecular composition of the extracellular matrix (ECM) 
in the fracture callus is disturbed. Methods: OP was induced at 10 weeks of age 
by ovariectomy and vitamin D3 deficient diet, and sham operated animals fed 
normal diet served as controls. Three months later a closed tibial fracture was 
made and stabilized with an intramedullary nail. After 3 and 6 weeks of 
healing, the animals were sacrificed and the fracture calluses examined with 
global gene expression, in situ mRNA expression and ultrastructural protein 
distribution of 4 bone remodeling markers, i.e. osteopontin (OPN), bone 
sialoprotein (BSP), tartrate-resistant acid phosphatase (TRAP), and cathepsin K 
(CTK). Results: The global gene expression showed a relative small number of 
differently regulated genes, mostly upregulated and at 3 weeks. The 4 chosen 
markers were not differently regulated and only minor differences in the in situ 
mRNA expression and ultrastructural protein distribution were detected. 
Conclusion: The gene expression and composition of fracture calluses are not 
generally disturbed in experimental OP.  
 
 
 
 
 
 
 
 
 
 
 
KEYWORDS  
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INTRODUCTION  
Osteoporosis (OP) is a multifactorial metabolic bone disease characterized by 
reduced bone density and quality, resulting in loss of mechanical strength and 
increased susceptibility to fracture. Women undergo a rapid phase of bone loss 
starting 2 to 3 years before ovarian failure, remaining up to 5 years after 
menopause, and in many cases, with postmenopausal OP as the final outcome 
[1, 2]. However, whether or to which extent this disrupted balance between 
bone formation and bone resorption [3, 4] influences healing of fractures in OP 
individuals remains to be answered.  
Fracture healing is a complex process taking place in order to fully restore 
anatomic and functional structure following injury, involving cell proliferation 
and differentiation, chemotaxis and synthesis of extracellular matrix (ECM). 
Although delayed healing of femoral neck fractures in OP patients has been 
reported [5], clinical data are limited. Due to ethical concerns and multiple 
confounding factors, most studies have been performed in animal models of 
postmenopausal OP. The ovariectomized (OVX) rat model has been approved 
by FDA [6] as a relevant model for the study of postmenopausal OP, 
mimicking postmenopausal trabecular bone loss when examined over relatively 
short periods of time. Impaired fracture healing has been reported in this model 
in early [7] and late stages [8], as evaluated by radiographic, 
histomorphometric and mechanical parameters. However, we recently 
demonstrated preserved BMD and mechanical strength of callus 6 weeks after 
fracture in experimental OP [9], in line with the findings by Kubo et al. at the 
same time point [8]. In support, Wheeler et al. [10] reports no difference 
between OVX and sham rats in mechanical strength of callus at 4, 6 and 8 
weeks after fracture. Thus, data are conflicting and, moreover only a limited 
number of studies look into the molecular events involved in fracture repair in 
OP.  
An additional predictor in the development of postmenopausal OP is vitamin D 
deficiency, which also may influence bone repair. Vitamin D deficiency is 
common among women with OP [11] and women with fractures regardless of 
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age [12], leading to accelerated bone resorption. In support, OVX rats with 
vitamin D depletion develop site-specific bone loss similar to what is observed 
in women with postmenopausal OP [13]. Additionally, oral administration of 
1,25(OH)2 vitamin D3 has recently been shown to improve fracture healing in 
OVX rats [14]. Interestingly, both estrogen [15] and vitamin D [16, 17] 
influences the expression and synthesis of ECM proteins and such proteins play 
important roles in mediating cellular function and may serve as important 
modulators of bone regeneration.  
Thus, we hypothesized that lack of estrogen and vitamin D deficiency 
influences the global gene expression as well as the synthesis and 
ultrastructural distribution of ECM molecules in the fracture callus, and 
consequently, the capacity of fracture repair. To test this hypothesis, we 
examined the global gene expression, and the in situ mRNA expression as well 
as ultrastructural protein distribution of two major phosphoproteins in bone, i.e. 
osteopontin (OPN) and bone sialoprotein (BSP), and two osteoclast enzymes, 
i.e. tartrate-resistant acid phosphatase (TRAP) and cathepsin K (CTK), in the 
callus 3 and 6 weeks after tibial fracture of vitamin D depleted OVX rats. Sham 
operated age-matched controls were used for comparison.  
 
METHODS 
Animals and tissue preparation 
All animal procedures were approved by the Norwegian Animal Research 
Authority. The experimental animal model was the same as previously [9]. In 
brief, 43 female Wistar rats (10 weeks of age with a mean body weight of 235 g 
(range 197-272 g)) were randomly assigned to two groups; Ovx-D 
(ovariectomy followed by vitamin D3-deficient diet and 3 months observation) 
or sham treated (abdominal skin incision and normal diet in the same period of 
time). Bone loss was validated by DXA in vivo before a closed fracture was 
made in the tibial midshaft and fixed with an intramedullary nail. Animals were 
killed at 3 and 6 weeks after fracture, and blood was collected before death. 
Animals for microarray analyses were killed by a phenobarbital overdose and 
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the dissected tibias were snap-frozen in liquid nitrogen. In the remaining 
animals, tissue was fixed by in vivo perfusion of 0.1 M phosphate-buffered 2% 
PFA during deep anaesthesia, the tibias dissected free from muscle and soft 
tissue and the nail carefully removed from a proximal port. Tibias were 
immersed in 2% PFA/0.5% glutaraldehyde/0.1 M phosphate-buffer and 
decalcified in 7% EDTA/0.5% PFA. Bone samples for transmission electron 
microscopic (TEM) analyses were subjected to low-temperature embedding in 
Lowicryl HM23 (Chemische Werke Lowi GmbH, Waldkraiburg, Germany) 
according to our established protocol [18]. Decalcified bone samples for in situ 
hybridization were embedded in paraffin according to a routine protocol. 
 
RNA isolation 
Calluses were cut from the tibial diaphyses, homogenized in Trizol reagent 
(Invitrogen, Carlsbad, CA) and total RNA was isolated according to 
manufacturer’s protocol as previously described [19]. RNA was further 
purified using QIAGEN RNeasy micro kit (Qiagen, Valencia, CA). Assessment 
of the concentration and quality of the total RNA samples were performed by 
spectrophotometry and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA).  
 
In situ hybridization (ISH) 
Total RNA was reverse-transcribed to cDNA using oligonucleotide primers 
listed in table 1. cDNAs were cloned with a Dual Promoter TA Cloning Kit 
(Invitrogen) and sequenced (Seqlab, Göttingen, Germany), and digoxigenin 
(DIG)-conjugated complementary RNA (cRNA) probes were synthesized with 
a DIG-labelling kit (Roche Diagnostics AS, Oslo, Norway) using T7 or Sp6 
RNA polymerase to yield probes in the sense or antisense orientation. For 
TRAP, cloning [20] and DIG-labelling [21] were performed as previously 
described. Hybridization was performed by modification of a previously 
described protocol [22]. Briefly, dewaxed and proteinase K-digested sections of 
paraffin-embedded callus samples were post-fixed in 4% PFA. Following 
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prehybridization (60 min, RT) in 50% formamide/2x SSC, sections were 
hybridized (over night, 42°C) with 5 ng probe in 50% formamide/2x SSC/7.5% 
dextran sulphate. High stringency washing was performed, and unbound probe 
was removed by RNAse-treatment (Ambion, Austin, USA). Hybridized probe 
was detected using an alkaline (AP)-conjugated sheep anti-DIG antibody 
followed by the AP-substrate nitroblue tetrazolium chloride/5-bromo-4-chloro-
3-indolyl-phosphate (Roche Diagnostics). 
 
Immunohistochemistry and immunogold labeling 
70 nm sections were cut from Lowicryl HM23-embedded tissue and mounted 
on formvar-coated nickel grids, and immunogold labeling was performed as 
previously described [18]. Briefly, after blocking with 5% BSA in PBS, grid-
mounted sections were incubated overnight with the primary polyclonal 
antibodies; anti-BSP (Chemicon, Temecula, CA), anti-TRAP 
(Immunodiagnostics Systems Ltd, Boldon, UK), anti-cathepsin K (Santa Cruz 
Biotechnology, Inc., CA.) and anti-OPN (raised in rabbits against a peptide 
sequence of the N-terminal end of the molecule). Bound antibodies were 
visualized by 90 min. incubation with 10 nm colloidal gold conjugated with 
protein A. Non-specific rabbit-IgG was used as a negative control.  
 
Analyses  
Microarray:  
The analysis was performed essentially as previously described [19], except 
that biotin-labelled cRNA probes were hybridized to GeneChip® Rat Genome 
230 2.0 Array (Affymetrix UK Ltd., UK). The quality of the RNA and cRNA 
probes were assessed by measuring the ratio between 5' and 3' mRNAs for 
beta-actin and GAPDH according to the Affymetrix-based test, and found to be 
highly satisfactory.  
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Light microscopy and ISH:  
Light microscopy was performed on paraffin-embedded callus specimens 
hybridized DIG-labeled cRNA probes for OPN, BSP, TRAP and CTK. Seven 
to 10 digital images (x 20) were sampled per callus section. Point counting of 
mRNA positive cells facing bone surfaces was performed using a 
semiautomatic image analyzer program (AnalySIS pro, Digital Soft Imaging 
System, Munster, Germany) with grid size of 25 µm x 25 µm [23]. In a parallel 
set of haematoxylin-stained sections, the corresponding callus area was 
identified and the total amount of mononuclear cells attached to bone surfaces 
counted (x 20). The ratio mRNA positive cells/total amount of bone surface 
cells was calculated for each set of corresponding images.  
 
TEM and immunogold analyses:  
Micrographs were obtained by systematic random sampling of 
cells/surrounding matrix and analyzed using the semiautomatic interactive 
image analyzer software AnalySIS® pro (Soft Imaging System, Munster, 
Germany). All identified osteoclasts and at least 4 osteoblasts in one to 3 
sections per animal were included in the analyses. An osteoclast was defined as 
a multinuclear giant cell attached to a matrix surface with characteristic 
membrane domains, i.e. ruffled border (RB) and/or clear zone (CZ) and an 
abundance of mitochondria in their cytoplasm [24]. An osteoblast was defined 
as a mononuclear cell attached to osteoid/bone matrix with a characteristic 
abundance of ER and Golgi complexes. A minimum of 4 images were sampled 
in each predetermined subcellular region according to our previously 
experience with protein distribution for BSP, OPN, TRAP and CTK [25, 26]. 
The gold particle density was calculated in the regions of interest (ROIs) 
according to the structural limits in the micrographs. Sections incubated with 
gold-labeled antibodies against BSP and OPN were analyzed with respect to 
both osteoblasts and osteoclasts, while only osteoclasts were studied in TRAP 
and CTK-labeled sections. The results are based on the analysis of up to 42 and 
24 osteoclasts at 3 and 6 weeks of healing, respectively.  For osteoblasts, a 
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minimum of 20 cells were analyzed in each group at 3 weeks, and 12 at 6 
weeks.  
 
Statistics 
Morphological results are given as mean with standard deviation (SD) in 
parentheses. One-way analysis of variance (ANOVA) and multivariate analysis 
of variance (MANOVA) were used for light and electron microscopic data, 
respectively. For the latter, interest was focused on whether the overall 
distribution pattern for each of the 4 proteins differed between the groups. 
Thus, for a protein, only differences in overall comparison between the groups 
using MANOVA, and not differences in tests between subjects, were 
considered. A p-value of less than 0.05 was considered significant.  
 
Statistical analysis of gene expression profiling: 
The 16 scanned chip images originating from the bone samples were processed 
using GCOS 1.4 (Affymetrix). The CEL files were imported into Array Assist 
software (v5.2.0; Iobion Informatics LLC, LaJolla, CA) and normalized using 
the PLIER (Probe Logarithmic Intensity Error) algorithm in Array Assist to 
calculate relative signal values for each probe set. In order to filtrate for low 
signal values, the MAS5 algorithm in Array Assist was used to create a data set 
of Absolute Calls, showing the number of present and absent calls for each 
probe set. The filtration was performed by eliminating probe sets containing ≥ 
13 absent calls across the data set, resulting in a reduction of probe sets from 
31,099 to 21,947. For expression comparisons of different groups, profiles 
were compared using paired t-test. The results are expressed as fold changes 
(FC), i.e. ratio of the mean signals between compared groups. Gene lists were 
generated with the criteria of p < 0.05 and FC > 2.   
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RESULTS 
Animal model of postmenopausal OP 
Ovx-D animals presented vitamin D3- and estrogen deficiency as well as 
decreased BMD in the vertebra and the femoral neck in comparison with sham 
treated (p < 0.001) [9]. The BMD of the callus areas did not differ between the 
groups at any time point (data not shown). After randomization, but prior to 
OVX and introduction of diet, the mean body weight was 4.7% lower in the 
Ovx-D group compared to sham (p = 0.02). However, despite pair feeding the 
Ovx-D group gained more weight compared to sham treated. The mean body 
weight was 8.6% and 12.9% higher in the Ovx-D group after 3 and 6 weeks, 
respectively (p < 0.001).  
 
Serum levels of 25-Hydroxyvitamin D and Estradiol 
25(OH)D < 25 nmol/l in serum was considered as vitamin D deficiency. The 
Ovx-D group presented levels of 25(OH)D < 18 nmol/l, and 94.4% showed  
undetectable (i.e. < 13 nmol/l) levels of 25(OH)D.  Postmenopausal estrogen 
levels was defined as serum estradiol < 0.10 nmol/l (Hormone Laboratory, 
Aker University Hospital, Oslo, Norway). All Ovx-D animals presented serum 
estradiol in the range of the reference values for postmenopausal state (i.e. < 
0.08 nmol/l).  
 
Fracture callus morphology 
The fracture calluses demonstrated hard callus formation with intense 
osteogenesis after 3 weeks in both groups. However, there was large inter-
individual variation in size and ratio of intramembranous to endochondral bone 
formation; some calluses exhibited mainly cartilage/fibrous tissue in the space 
between the areas of subperiosteal bone formation, while others exhibited 
predominantly intramembranous bone formation beneath the periosteum 
adjacent to the fracture site (fig.1). Resorbing clasts were observed both on 
cartilaginous and osseous surfaces. By light microscopy no obvious differences 
were detected between Ovx-D and sham treated rats with respect to matrix 
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resorption activity, vascular invasion or endochondral ossification. At 6 weeks 
of healing, the same light microscopic heterogeneity was evident. However, a 
general tendency towards a decline in the remodeling activity was observed.  
 
Gene profiling 
At 3 weeks of healing, 155 annotated genes and 88 expressed sequence tags 
(ESTs) were differently regulated in Ovx-D versus sham, out of which 35 
genes were downregulated and 120 upregulated. At 6 weeks, 22 genes and 8 
ESTs were differently regulated, out of which 6 genes were downregulated and 
16 upregulated in Ovx-D (fig. 1 and suppl. table 2). No significant differences 
in the mRNA levels for OPN, BSP, TRAP or CTK between the groups or 
between the different time points were detected (table 2). Among genes with 
suggested or known roles in bone metabolism, fibroblast growth factor 23 
(FGF23) was down-regulated (p=0.02) and interleukin 17 (IL-17) receptor A 
was upregulated (p=0.01) in the OP group at 3 weeks.  
 
Localization of OPN, BSP, TRAP and CTK mRNA  
OPN and BSP mRNA were detected predominantly in osteoblastic cells and in 
some chondrocytes in the bone-cartilage transitional zone, but were 
undetectable in resorbing multinuclear cells. However, BSP mRNA expression 
in osteoclast progenitors cannot be excluded. CTK and TRAP mRNA were 
detected in multinucleated cells attached to bone/cartilage surfaces. In addition, 
several non-attached mononuclear cells, presumably osteoclast progenitors, 
were positive (fig. 2).   
 
Ratios of mRNA expressing cells on bone surfaces 
Compared to sham treated animals, Ovx-D animals exhibited increased ratio of 
OPN mRNA expressing cells at 3 weeks (p=0.05) but decreased ratio of BSP 
mRNA expressing cells at 6 weeks (p=0.01). Ratios for TRAP or CTK did not 
differ between the two groups. In the Ovx-D group, ratios for BSP (p=0.04), 
OPN (p=0.01) and CTK (p=0.04) decreased from 3 to 6 weeks. No differences 
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between the time points were observed among the mRNAs above for sham 
treated animals (table 3). 
 
Ultrastructural protein distribution  
The most intense accumulation of markers for both BSP and OPN was 
observed at electron dense extracellular areas representing mineralization 
front/cement lines (fig. 3), and to a lesser extent, diffusely spread, in the 
mineralized matrix of woven bone. BSP exhibited a characteristic pattern with 
label being localized to discrete sites in the bone matrix corresponding to areas 
of early mineral deposition (fig. 3b). Both BSP and OPN labeling showed a 
tendency towards increased intensity in the matrix facing the CZ of osteoclasts, 
the latter being most pronounced. No signal for BSP or OPN was found in the 
cartilaginous areas. Immunoreactivity for TRAP and CTK was consistently 
increased in the osteoclast cytoplasm and partly also in the matrix facing the 
RB. Lower levels were observed in the matrix facing the CZ. Intraluminal 
labeling of vessels was used as a measure of non-specific binding/background 
and was low throughout the experiments, as was the nuclear labeling (data not 
shown).  
 
Quantitative immunogold analysis  
The immunogold signal for OPN in osteoclasts was different for Ovx-D versus 
sham animals after 6 weeks (p = 0.04) with markedly increased labeling 
intensity in the matrix facing the RB of osteoclasts in Ovx-D animals, although 
no differences were observed with respect to osteoblasts at neither time point. 
For BSP no differences were detected between groups or time points (table 4).  
CTK showed different distribution with respect to osteoclasts between the 
groups after 3 weeks (p=0.03) with generally increased labeling intensity in all 
compartments measured for osteoclasts in the Ovx-D animals. Moreover, CTK 
labeling in the sham treated animals differed from 3 to 6 weeks (p=0.01). 
TRAP distribution did not differ between the groups or between different time 
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points. Interestingly, TRAP labeling accumulated in the matrix facing the RB 
of osteoclasts at 3 weeks in both groups, but not at 6 weeks (table 5).   
 
DISCUSSION  
The present study addresses fracture healing in vitamin D-depleted OVX rats at 
the molecular level over a 6 weeks period. Estrogen and vitamin D exert their 
effects on bone in a spatial manner which differs between metabolic active 
trabecular bone and weight bearing cortical bone. Although vitamin D initially 
was reported to stimulate bone resorption in vitro [27], more recent in vivo 
findings indicate that active vitamin D analogues rather have an inhibitory 
effect on bone resorption, at least in a state of high turnover [28]. This 
inhibitory effect is reported to be less active in trabecular bone [29]. In a 
similar manner, estrogen deficiency following OVX results in bone loss at 
discrete sites in the skeleton with most pronounced effect on trabecular bone 
[30].  
Several genes associated with signal transduction, lipid and protein 
metabolism, ionic and protein transport, neuropeptide and G protein signaling 
were differently regulated in our Ovx-D rat model. Many of these processes 
represent metabolic systems capable of maintaining bone homeostasis and 
tissue turnover. Most genes were expressed in an increased fashion in Ovx-D 
compared to Sham, in line with other reports on gene profiling of intact bone in 
OP [31]. Interestingly, no significant differences were detected among genes 
encoding NCPs with known functions in bone metabolism. 
 At 3 weeks a 7-fold more genes were differently regulated compared to 6 
weeks, and consequently, changes in the healing pattern in OP would be 
expected in early stages. Among the differently regulated genes, the genes for 
interleukin 17 (IL-17) receptor A and fibroblast growth factor 23 (FGF23) were 
up- and downregulated in Ovx-D after 3 weeks, respectively. IL-17 plays a role 
in bone loss in rheumatoid arthritis [32], and FGF23 has recently been 
suggested as a putative marker of bone healing; decreased FGF23 mRNA 
expression being related to delayed fracture healing [33]. However, microarray 
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data are overall data representing the whole callus and, consequently, 
differences within the callus are not detected.  
In our molecular studies we focused on 4 molecules with roles in bone 
remodelling taking place in the callus, and, putatively, being influenced by lack 
of estrogen and vitamin D depletion. E.g. OPN is suggested to play roles both 
during osteoclast development/activity [34] and during matrix mineralization 
[35]. Furthermore, OPN null mice are resistant to ovariectomy-induced bone 
loss [36] and display disturbed fracture healing [37], suggesting a role for OPN 
during estrogen deficiency-related bone loss as well as in bone repair. 
Moreover, OPN is under the influence of both estrogen and vitamin D [15, 17]. 
mRNA expression for OPN, BSP, TRAP and CTK in cell types was distributed 
as previously described in intact bone tissue [20, 25, 38]. Ovx-D animals 
presented increased ratio of OPN mRNA expressing cells and indicated 
decreased ratio of BSP mRNA expressing cells at 3 weeks, and significantly 
reduced ratio for BSP after 6 weeks of healing. These observations are in line 
with the reported inverse regulatory role of vitamin D for these proteins in vivo 
[39]. The observed increase in OPN and subsequent decline in BSP indicate 
suppressed osteoblastic differentiation in the Ovx-D group.  
In Ovx-D rats at 3 weeks relative to 6 weeks, there was a significant decline in 
the ratio of cells expressing mRNAs for OPN, BSP and CTK, but not for 
TRAP. Thus, the decreased number of cells producing these bone turnover 
biomarkers in the Ovx-D group at 6 versus 3 weeks indicates a decline in 
synthetic activity/bone remodeling and a more remodeled callus. The latter 
supports the findings of Cao et al. [40], reporting a histologically more mature 
callus with preserved mechanical properties in OP rats versus sham treated rats.  
Quantitative immunoelectron microscopy showed only minor differences in 
labeling (table 4, 5). The apparent inconsistence between our ISH and 
immunogold data is most likely due to the fact that the two data sets represents 
different aspects of callus turnover; while ISH data represent mRNA 
expression and thus, protein synthesis, immunogold data reflect the present 
amount of protein in the tissue, which is the net result of synthesis, secretion 
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and degradation. That only minor differences of protein synthesis and tissue 
distribution were detected between the groups is supported by other recent 
studies [41, 42].  
 As with any animal model, there are limitations in simulating clinically 
relevant conditions. The calluses showed considerable heterogeneity both by 
macroscopic appearance and by histology. Mechanical instability during 
fracture healing promotes cellular differentiation in the direction of 
endochondral bone formation [43], suggesting variable degrees of fracture 
fixation in our experiment. Since mechanical stress is shown to influence the 
mRNA expression in bone cells [44], this may have influenced our results by 
causing a relatively large variation among the samples. Furthermore, minimal 
trauma-fractures in OP patients are mostly localized to the proximal femur, the 
vertebral column and distal forearm [45], i.e. areas of high trabecular to cortical 
ratio. Thus, the present study concerns fracture healing in cortical bone and it is 
possible that this type of bone healing is less influenced by estrogen- and 
vitamin D deficiency.  
 
In summary, several genes are differently regulated in OP induced by 
ovariectomy and vitamin D depletion, mostly in an early stage and the majority 
in an increased fashion, although no genes encoding NCPs with known 
function in bone metabolism were differently expressed. On the background of 
only minor differences in the synthesis and protein expression of OPN, BSP, 
TRAP and CTK in callus between Ovx-D and sham treated animals, our results 
suggest that the molecular composition of the fracture callus is not markedly 
skewed in OP.  
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TABLES 
 
Table 1. Primer sequences for DIG-labeled cRNA probes 
   
Sequence name 
 
Sequence forward Sequence reverse 
   
cathepsin K 
 
bsp 
 
osteopontin 
5’-agacgcttacccgtatgtgg-3’ 
 
5’-atggagatggcgatagttcg-3’ 
 
5’-ctctgatcaggacagcaacg-3’ 
 
5’-tggagagaagggaagcagag-3’ 
 
5’-tgaaacccgttcagaaggac-3’ 
 
5’-tcagggcccaaaacactatc-3’ 
 
Table 2. Gene profiling. OP versus sham treated animals 
 
    
FC 
Ovx-D vs. Sham 
Gene ID Gene title Gene 
symbol 
3 weeks 6 weeks 
     
1367942_at Tartrate-resistant acid phosphatase 5 
(TRAP) 
 
Acp5 1.26 1.22 
1367581_a_at Secreted phosphoprotein 1 (OPN) 
 
 
Spp1 1.74 0.83 
1368416_at Integrin binding sialoprotein (BSP) 
 
Ibsp 0.91 1.00 
1369947_at Cathepsin K (CTK) 
 
 
Ctsk 1.74 0.91 
 
Fold change (FC) > 2. No significant differences between the two groups.  
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Table 3. Ratios of mRNA expressing cells to the total amount of cells attached to bone surfaces  
     
mRNA Group n 3 weeks 6 weeks 
     
Ovx-D 6/5 0.20 (0.14) 0.068 (0.053) TRAP 
Sham 7/4 0.11 (0.052) 0.18 (0.14) 
Ovx-D 7/5 0.17 (0.095)*b 0.059 (0.032) CTK 
Sham 7/4 0.18 (0.094) 0.14 (0.14) 
Ovx-D 7/5 0.33 (0.15)*a/*b 0.12 (0.047) OPN 
Sham 7/4 0.19 (0.059) 0.12 (0.085) 
Ovx-D 7/5 0.21 (0.14)*b 0.022 (0.034) BSP 
Sham 7/4 0.32 (0.19) 0.18 (0.089)* 
     
Results are given as mean (SD). (n): number of animals in OP/sham, (*a) Significant differences 
between the groups (p < 0.05), (*b) Significant differences between 3 and 6 weeks in the group  
(p < 0.05). 
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Table 4. Protein distribution of OPN and BSP in the fracture callus at 3 and 6 weeks  
 
          
      3 weeks       6 weeks     
      
  OPN BSP OPN BSP 
          
Cell 
type ROI Ovx-D Sham Ovx-D Sham  Ovx-D Sham Ovx-D Sham  
    n=5 n=6 n=5 n=6 n=4 n=4 n=4 n=4 
          
OB Nuc. 2.38 (3.07) 2.30 (1.00) 4.06 (3.56) 2.98 (1.67) 1.32 (0.92) 1.25 (0.87) 1.70 (0.57) 1.69 (0.70) 
  Cyt. 2.84 (3.42) 2.66 (1.18) 3.66 (2.32) 3.69 (1.50) 1.04 (0.41) 0.99 (0.21) 1.41 (0.47) 2.06 (1.37) 
  O 1.83 (1.04) 1.94 (1.40) 6.63 (6.83) 2.52 (0.56) 1.89 (0.30) 1.65 (0.87) 1.62 (0.27) 1.83 (0.24) 
  MF 
57.58 
(28.38) 
38.11 
(12.11) 
421.22 
(343.93) 
311.52 
(30.65) 
42.43 
(5.16) 
51.18 
(18.89) 
176.40 
(27.92) 
308.72 
(58.98) 
  WB 3.66 (0.52)  3.56 (2.98) 
116.87 
(102.09) 
75.66 
(29.31) 1.75 (0.66) 3.03 (2.37) 32.50 (8.94) 
81.51 
(39.75) 
  BG 0.14 (0.09) 1.26 (0.96) 1.95 (1.47) 1.16 (0.60) 0.19 (0.04) 0.39 (0.18) 
17.79 
(17.79) 0.40 (0.13) 
          
          
    n=5 n=5 n=5 n=5 n=3 n=3 
n=2 
(*n=1) 
n=3 
(*n=2) 
          
OC  Nuc. 0.90 (0.46) 1.12 (0.26) 3.61 (0.83) 1.99 (0.73) 0.69 (0.18) 0.82 (0.40) 2.58 (-)* 1.90 (0.97) 
  Cyt. 1.28 (0.24) 1.77 (1.13) 4.38 (1.65) 2.67 (0.90) 0.89 (0.10) 1.25 (0.22) 4.89 (1.33) 3.18 (0.38) 
  RBc 0.69 (0.31) 2.17 (0.36) 2.91 (1.71) 2.58 (0.76) 1.30 (1.17) 1.00 (0.46) 3.73 (1.66) 1.85 (0.47) 
  RBm  2.30 (1.75) 2.58 (1.18) 39.87 (33.39) 29.67 (8.45) 
26.41 
(17.38) 3.55 (1.54) 
69.11 
(36.10) 16.36 (7.84) 
  CZc 0.95 (0.52) 2.83 (0.60) 5.81 (1.12) 5.64 (2.27) 1.47 (-) 1.19 (0.44) 9.02 (-)* 3.86 (0.14)* 
  CZm  7.13 (4.29) 6.26 (3.08) 34.74 (23.85) 
58.34 
(60.52) 3.23 (-) 
5.03 
(3.50)** 36.80 (-)* 
57.99 
(28.94)* 
  BG 1.21 (1.85) 0.68 (0.18) 2.40 (0.30) 1.76 (1.05) 0.44 (0.09) 0.51 (0.11) 1.43 (0.05) 1.31 (0.25) 
 
Values are mean gold particles per um
2
. *reduced number - cell domain not found in all animals. ** p < 
0.05. Abbreviations; ROI = region of interest/compartment, OB = osteoblast, OC = osteoclast, nuc. = 
nucleus, cyt. = cell cytoplasm, O = osteoid, MF = mineralization front, WB = woven bone, RBc = cell 
cytoplasm facing the ruffled border, RBm =  extracellular matrix facing the ruffled border,  CZc = cell 
cytoplasm facing the clear zone, CZm = extracellular matrix facing the clear zone, BG = background, i.e. 
capillary lumen.   
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Table 5. Protein distribution of TRAP and CTK in the fracture callus at 3 and 6 weeks of healing 
  
 
   3 weeks     6 weeks   
      
  TRAP CTK TRAP CTK 
          
Cell 
type ROI Ovx-D Sham Ovx-D Sham  Ovx-D Sham Ovx-D Sham  
    n=5 n=5 n=3 n=5 n=3 n=3 n=2 n=3 
          
OC  Nuc  1.04 (0.44) 0.77 (0.37) 1.22 (0.40) 0.74 (0.17) 1.37 (1.10) 0.60 (0.32) 0.94 (0.05) 1.10 (0.46) 
  Cyt 6.60 (1.66) 6.33 (2.70) 6.00 (1.92)** 3.67 (0.25) 4.98 (1.33) 2.93 (0.40) 5.56 (3.77) 4.12 (1.04) 
  RBc 2.72 (1.28) 2.64 (1.83) 1.77 (1.04) 1.58 (0.34) 0.78 (0.49) 0.57(0.16) 1.48 (1.28) 1.73 (0.68) 
  RBm 12.76 (6.86) 13.76 (9.74) 4.13 (2.43) 3.60 (0.73) 2.46 (0.85) 2.93 (2.00) 5.85 (4.23) 3.07 (1.82) 
  CZc 1.54 (0.32) 1.33 (0.70) 1.70 (0.41) 1.98 (0.55) 1.43 (1.12) 0.92 (0.43) 2.07 (1.22) 3.80 (1.84) 
  CZm  5.95 (3.34) 12.65 (9.07) 2.82 (1.31) 2.40 (0.27) 2.07 (0.48) 2.78 (2.40) 5.82 (-) 2.50 (1.36) 
  BG 1.03 (0.53) 0.65 (0.34) 0.68 (0.39) 0.76 (0.24) 1.10 (0.82) 0.62 (0.21) 0.82 (0.16) 0.88 (0.46) 
 
Values are mean gold particles per um
2
  *reduced number - cell domain not found in all animals ** p = 0.05 
Abbreviations; ROI = region of interest/compartment, OC = osteoclast,  nuc. = nucleus, cyt. = cell cytoplasm, O 
= osteoid, MF = mineralization front, WB = woven bone, RBc = cell cytoplasm facing the ruffled border, RBm =  
extracellular matrix facing the ruffled border,  CZc = cell cytoplasm facing the clear zone, CZm = extracellular 
matrix facing the clear zone, BG = background, i.e. capillary lumen. 
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FIGURES 
Fig. 1. Differentially expressed genes in callus of the Ovx-D group 
 
Microarray analysis showed a larger number of annotated genes and expressed 
sequence tags (ESTs) differently regulated in the Ovx-D group (fold change > 
2) compared to sham, the majority in an increased fashion and mostly after 3 
weeks of healing. p < 0.05.  
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Fig. 2. Callus morphology after 3 weeks of healing 
 
Light microscopic callus morphology showing two different animals in the 
Ovx-D group at 3 weeks of healing. Both Ovx-D and sham treated animals 
exhibited relatively large inter-individual variation in the composition and size 
of callus after 3 as well as 6 weeks of healing. 2a A large fracture callus with 
massive accumulation of fibrous tissue (F), cartilage (C) and endosteal bone 
formation (EBF). 2b A smaller callus with endosteal and subperiosteal bone 
formation (SPBF). MC, marrow cavity. H&E, x 4  
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Fig. 3. Expression of OPN, BSP, TRAP and CTK in the fracture callus 
 
OPN, BSP, TRAP and CTK mRNA positive cells in fracture callus at 3 weeks 
visualized by in situ hybridization. OPN mRNA (3a) and BSP mRNA (3c) 
positive osteoblasts, and TRAP mRNA (3b) and CTK mRNA (2d) positive 
osteoclasts (arrows). WB, woven bone. CB, cortical bone. Paraffin-embedded 
sections, x 20. 
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Fig. 4. Ultrastructural distribution of BSP and OPN in mineralized bone 
 
Characteristic ultrastructural protein distribution of OPN and BSP in fracture 
callus at 3 weeks. 4a Immunogold signaling for OPN with distinct 
accumulation along a cement line (arrows). 4b Intense BSP signaling at early 
focus of mineralization, i.e. “mineralization noduli” (arrows). OC, osteocyte 
canaliculi. Lowicryl HM23 embedded, x 43,000  
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